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Abstract 
 
 
Vesicular Stomatitis Virus (VSV) is a simple, enveloped, nonsegmented negative-
strand RNA virus and is the prototype rhabdovirus to study viral entry, transcription, 
replication, and assembly.  The matrix protein (M) of VSV is a central component of the 
viral replication cycle.  While being the smallest of the viral proteins it is multifunctional 
and is involved in uncoating, cytopathic effects (CPE), and assembly of the virus.  M 
protein interactions involved in the uncoating and assembly of VSV have been examined 
in this dissertation.  
 
Uncoating of VSV involves dissociation of M from the ribonucleoprotein core 
(RNPs) of the virus.  Current models of VSV uncoating propose that following 
membrane fusion M protein is released from the RNP with subsequent diffusion of M 
into the cytoplasm and distribution of some of the released M to the nucleus of a host 
cell.  The studies in Chapter 2 investigated where in the endocytic pathway uncoating 
occurs, where M is located following uncoating, and the role of the cytoskeleton in 
distribution of input M by using a VSV, containing fluorescent M protein (rVSV-M-
Lumio-Green).  I found that uncoating occurs primarily in early endosomes and results in 
the majority of M remaining associated with the endosomal membrane which eventually 
localizes to the perinuclear recycling endosomes.  A small fraction of M, which is 
presumably released into the cytosol, gets delivered to the nuclear envelope, and I found 
that the typical polymerized actin or microtubules within host cells were not required for 
distribution of M to the nuclear envelope.  
 
Uncoating and assembly of the VSV genome occurs on membranes within the 
cytoplasm of the host cell.  Exactly how both of these processes can occur in the same 
environment (e.g. the cytoplasmically exposed membrane surface) without modification 
of M protein by phosphorylation, cleavage, or some other change has been an intriguing 
question in the field.  In Chapter 3 I present results showing a pH effect on the M-Lumio-
Green protein fluorescence in vitro and during the endocytosis of virions which was 
dependent on G protein.  I also observed that low pH enhanced the release of M from 
rVSV-wt virions, which suggested that acidification of the virus interior results in the 
dissociation of M contacts within the virus enhancing the uncoating process.     
 
An exposed protease-sensitive loop located between amino acids 120 to 129 of M 
has been shown to be important for M protein self-association and has been proposed to 
be crucial for assembly of virions.  This knowledge comes from protease treated, purified 
M protein and not from mutagenesis studies.  In Chapter 4 I examined mutations in the 
exposed loop and in particular a conserved aspartate at residue 125 of a conserved LXD 
sequence.  I found that virions with mutations at residue 123 or 125 of the LXD motif 
have two phenotypes; 1) an assembly defect and 2) reduced viral protein synthesis 
starting at 4 hours post infection.  These two phenotypes have not been separated 
genetically and the LXD motif may represent a motif of M involved in assembly and 
support of VSV protein translation.   
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Chapter 1: Introduction 
 
 
Vesicular Stomatitis Virus (VSV) 
 
 
Vesicular stomatitis virus (VSV): the prototype Rhabdovirus.  VSV, is a 
simple, enveloped, nonsegmented, negative-strand RNA virus in the family 
Rhabdoviridae, and the order Mononegavirales.  The Paramyxoviridae, Bornaviridae, 
and Filoviridae families complete the order Mononegavirales.  Virions from these four 
families have a similar genome organization and share some properties of their 
transcription, replication, and assembly. 
 
The Rhabdoviridae family includes three genera:  the Lyssavirus genus, which 
includes rabies and the rabies-like viruses, the Emphemerovirus genus, which includes 
bovine ephemeral fever virus (BEFV), and the Vesiculovirus genus, which includes VSV.  
VSV, is the prototype virus from the Rhabdoviridae family, and has been a platform of 
study for viral entry, transcription, replication, and assembly for many years.  This is a 
direct result of its simple genome, broad cell tropism, and ability to grow to high titers in 
cell culture.  There are two main serotypes of VSV found in the Western Hemisphere: the 
Indiana and New Jersey serotypes.  Outside of the laboratory, mammals, mosquitoes, 
mites, and sand flies are among the hosts that can be infected by both serotypes.  Of 
particular importance is the economic impact of the disease it causes, vesiculo stomatitis, 
in cattle, swine, and horses (121).  This disease is characterized by vesicular lesions on 
the hooves, teats, and gums of infected animals, which are similar characteristics to foot 
and mouth disease.  Though rare, VSV infections of humans can occur by accidental 
exposure in the laboratory or contact with infected animals in rural areas (56).  Infection 
can result in flu-like symptoms for a few days, with vesicular lesions of the mouth, or no 
symptoms at all. 
 
While not a human pathogen, VSV is a member of an order with many important 
human pathogens such as rabies virus, Ebola virus, Marburg virus, human parainfluenza 
virus, respiratory syncytial virus, and measles virus.  Because virions found in the 
Mononegavirales share some aspects of their viral replication cycles, further insight into 
VSV’s viral cycle can open a window to important information about the viral cycles of 
the human pathogens in this order.  In addition to being a model, recombinant VSVs 
(rVSVs) are being tested as vaccine vectors and viral cytolytic vectors to fight certain 
cancers and HIV infections (185, 193).  Developing a clearer understanding of VSV’s 
viral cycle could help make these vectors more effective and safe for use in humans. 
 
 
A brief history of VSV in the Americas.  The two main serotypes of VSV found 
in the United States, the Indiana and New Jersey, were isolated in the 1920s.  In 1925 a 
shipment of cattle that arrived in Richmond, Indiana from Missouri developed vesicular 
lesions in the mouth and were associated with an outbreak of vesicular stomatitis in the 
area.  Virions isolated from the lesions were able to infect horses and could be serially 
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passaged in animals.  This virus then became the VS-Indiana strain (39).  An outbreak of 
vesicular stomatitis occurred among cattle in New Jersey during the year of 1926.  The 
agent responsible for this disease was found to be filterable and that it could infect cattle, 
guinea pigs, and horses.  However, it was found that this virus was serologically different 
from the Indiana strain and became known as the VSV-New Jersey strain (38, 39).  The 
Indiana and New Jersey serotypes have been the most commonly isolated strains in the 
Americas.  In the United States, the last Indiana outbreak occurred in 1965 (96), whereas 
New Jersey was responsible for outbreaks in the United States in 1944, 1949, 1957, 1959, 
1963, 1982-83, 1985, 1995, 1997, 1998, and 2005 that were mainly located in the west 
(1, 19, 143, 144).  However, there is an island (Ossabaw) off of the coast of Georgia that 
is the only known place to have VSV-New Jersey as an enzootic disease where it is 
believed that a sand fly (Lutzomyia shannoni) on the island may be the vector that passes 
the virus to the feral pigs, horses, deer, cattle and raccoons that inhabit it (191). Besides 
the United States, VSV can also be found in other parts of the Americas including 
southern Mexico, Central America, and northern South America where sporadic 
epidemics emerge from the tropical areas (121). 
 
 
VSV Composition and Replication 
 
 
The composition of VSV.  VSV is composed of an 11 Kb, negative-strand RNA 
genome that contains five genes (3’-N-P-M-G-L-5’).  These genes encode the 
nucleocapsid protein (N), the phosphoprotein (P), the matrix protein (M), the 
glycoprotein (G), and the large polymerase protein (L) (Fig. 1-1).  The virion’s structure 
is composed of a helical nucleocapsid, containing L-P-N-RNA-M, surrounded by a 
membrane derived from an infected host cell membrane which has transmembrane 
trimeric G proteins protruding from it.  These bullet-shaped VSV particles are an average 
of 180 nm long and 75 nm wide with around 400 trimeric G protein spikes on the exterior 
of the viral membrane and about 1,800 molecules of M protein between the nucleocapsid 
core and the viral membrane.  The RNA genome is encapsidated by N protein with 
around 1,200 molecules of this protein tightly complexed to the RNA like beads along a 
string.  The RNA-dependent RNA polymerase, consisting of the L and P proteins, is 
associated with this ribonucleoprotein complex and these proteins are present at 50 and 
500 molecules per virion, respectively.  This L-P-N-RNA complex makes up the 
ribonucleoprotein particle (RNP) which is coiled into a tightly packed helix of around 35 
turns inside the viral membrane.  The M protein condenses the RNP into this tightly 
packed helix, which, when condensed as described, is referred to as the skeleton. 
 
 
The viral replication cycle of VSV.  VSV takes advantage of host cell machinery 
to replicate.  There are five stages involved in VSV replication that lead to progeny 
virions. The first stage consists of adsorption of virions, via the G protein, to an 
unidentified receptor on the host cell membrane and entering the cell through the 
clathrin-mediated endocytic pathway (139).  The second stage, uncoating, involves the  
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Figure 1-1. VSV schematic. 
Electron Micrograph of VSV particles with a cartoon denoting viral proteins (note the 
skeleton within the viral envelope of the cartoon) and their location within virions and an 
SDS-PAGE gel. L, large polymerase protein, G, glycoprotein, P, phosphoprotein, N, 
nucleocapsid protein, M, matrix protein.  Illustration from the lab of Michael A. Whitt, 
Ph.D. with permission from Clint Robison, Ph.D (personal communication).
 3
pH-dependent fusion of the viral membrane with the endosomal membrane through the 
activity of G protein which results in the release of the RNP core into the cytoplasm 
where replication occurs (139).  Either directly after or concomitant with membrane 
fusion, M protein dissociates from the RNP core resulting in decondensation of the 
skeleton, which when combined with membrane fusion results in completion of VSV 
uncoating (130, 174).  However, the trigger for M protein dissociation within a host cell 
is unknown at this time.  In the third stage, the decondensed, RNP serves as a template 
for transcription of viral mRNAs by the packaged RNA-dependent RNA polymerase.  
VSV transcription, like other nonsegmented negative strand RNA viruses, is sequential 
and polar where each of the five genes is transcribed in the order that they appear from 
the 3’ end of the genome (87, 88, 130).  There is a ~30% reduction in the amount of 
downstream message that is made when compared to the upstream message, resulting in 
N mRNA being the most abundant message and L mRNA the least abundant (203).  The 
viral mRNAs are capped, methylated, and polyadenylated by the VSV polymerase (85, 
186).  Once primary transcription has occurred, stage four begins where the VSV 
polymerase uses the same encapsidated genomic RNA as a template to synthesize a full-
length, anti-genomic replicative intermediate (RI).  The RI functions as a template for 
replication of more genomic RNA which can be used in subsequent rounds of 
transcription, replication, and for packaging into progeny virions.  Stage five involves the 
assembly of the VSV virion which can be divided into three phases: (i) encapsidation of 
newly made genomic RNA by the N protein and subsequent association of L and P 
forming the RNP, (ii) condensation of RNP by the M protein and association with the 
plasma membrane forming the skeleton, and (iii) budding from the host cell surface by 
envelopment of the skeleton and then release of the progeny virion.  The last two phases 
of stage five are attributed to the activity of M protein (10, 67, 100, 130, 132, 153, 154). 
 
 
The VSV Matrix (M) Protein 
 
 
The M protein.  M, the smallest of the virion’s proteins at 229 amino acids (26 
KDa), is an unglycoslylated protein that is present at about 1800 copies per virion.  It is 
composed of a pleomorphic N terminus (residues 1-58) and a globular C terminus 
(residues 59-229) made up of 7 beta sheets that “cap” three alpha helices (Fig. 1-2).  The 
M protein plays a key role in virus assembly and budding at the host cell’s plasma 
membrane.  It has the ability to bud vesicles from cells when it is expressed in the 
absence of other VSV proteins (97), a property attributed to its PPxY (PY) motif that 
binds WW domains of cellular proteins involved in multivesicular body formation (80).  
Around 10% of VSV M is associated with membranes in infected cells, whereas the 
remaining amount is cytoplasmic (30, 31, 146, 147) and nuclear (133).  M protein, being 
multifunctional, is also involved in the cytopathic effects inflicted on host cells infected 
by the virus.  These effects include inhibition of host mRNA expression (14), translation 
(181) and nucleocytoplasmic transport (53), and the disruption of host cell cytoskeletal 
organization (92).  Over the past thirty years, many discoveries have been made 
concerning M protein’s role in virus assembly and host cell cytopathic effects.  However, 
key questions still exist, including: what causes the matrix protein to dissociate, where  
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Figure 1-2.  Crystal structure of the VSV M protein. 
(A) Schematic of full-length M and the M proteins proteolytically cleaved by trypsin and 
thermolysin, respectively.  (B) Structure of the thermolysin cleaved globular core of the 
M protein with 7 beta sheets surrounding 3 alpha helices also shown in (C).  The exposed 
loop is located at amino acids 120 to 129.  Reprinted with permission from Marcel 
Knossow, Gaudier, M., Y. Gaudin, and M. Knossow. 2002. Crystal structure of vesicular 
stomatitis virus matrix protein. Embo J 21:2886-92, (66).
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does it distribute within cells during viral uncoating events, and which region(s) of M 
interact during virion assembly? 
 
 
M protein and membrane association.  A fraction of M protein within infected 
cells is associated with the inner leaflet of the plasma membrane (31).  This localization 
at the plasma membrane can occur even in the absence of other viral proteins.  There are 
no significant stretches of hydrophobic residues in the M protein that would serve as a 
transmembrane region (120) nor are there any modifications by fatty acids to explain its 
plasma membrane association.  The N terminal region of M has been implicated in the 
interaction with membranes via the hydrophobic, photo-reactive probe 125I-TID (120).  
Also the N terminus of M contains a highly basic region which might be able to interact 
with the negatively charged head groups of the membrane phospholipids by electrostatic 
interactions.  Though a logical assumption, deletion of the 43 residues in the N terminus, 
which includes the basic region, only weakens membrane association and does not 
completely reduce the interaction of M with membranes (30).  This observation points to 
perhaps another membrane interaction domain, which is speculated to be between 
residues 88-119 (217) and/or a hydrophobic surface located close to a hydrophobic loop 
that is surrounded by conserved basic residues (30, 66).  VSV M cell membrane 
association is necessary for its budding activity (119) and this activity is important for 
virion release and hence virus assembly (91).  
 
 
Formation of skeletons by M.  Along with M association at the inner leaflet of 
the plasma membrane, RNP condensation by M is also important in VSV assembly (132) 
and this occurs at the plasma membrane (157).  It has been shown that cytosolic and 
membrane bound M can bind to RNPs but the proteins have a higher affinity for RNPs 
isolated from virus versus cytosolic RNPs (57).  These observations suggested that M 
binding to RNPs is dependent on a change in cytosolic RNPs at the plasma membrane 
and recent evidence has led to a model where G and RNPs associate in microdomains at 
budding sites and then M is incorporated (195).  Treating purified VSV virions with 
detergent at low ionic strength solubilizes the viral membrane and G protein liberating 
the highly condensed, tightly coiled skeleton which consists of the RNP and M protein 
(153, 154).  When these skeletons are placed in the presence of high ionic strength buffer 
(~250mM NaCl) the result is decondensation of these compact structures by dissociation 
of M protein.  The decondensed RNPs can reform skeletons by dialyzing away the salt in 
the presence of M protein.  The association of M and subsequent condensation of RNPs 
into skeletons results in an inhibition of viral transcription in vitro as well as in infected 
cells (26, 44, 166).  The N terminus of M is essential for binding to the nucleocapsid in 
vitro (30, 158), but proteolytic cleavage of skeletons showed that the N terminus is 
exposed to proteases when bound to nucleocapsids suggesting an indirect interaction 
between this region and nucleocapsids (100).   
 
 
Membrane associated M protein and its association with the glycoprotein (G) 
protein.  The G protein of VSV is incorporated into virions at budding sites along the 
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plasma membrane and this has been shown to occur in microdomains that are not 
detergent resistant (21) but that are enriched for sphingomyelin and cholesterol (111, 125, 
126).  It has been suggested that G is the protein that forms budding sites where the 
internal viral components can then finish the process of forming a progeny virion (21).  G 
and M have been shown to interact within virions by chemical crosslinking experiments 
(46) and within cells using fluorescence photobleaching assays which showed mutations 
in the M protein have an effect on the mobility of the G protein on the surface of the cells 
(173).  Purified M protein and skeleton complexes were also shown to interact with and 
stabilize G protein into trimers in in vitro assays (128).  However, the amino acids of the 
G protein cytoplasmic tail are not specific to this interaction.  In fact the cytoplasmic tail 
of G just needs to be 1 amino acid in length in order to be incorporated into VSV virions 
(210).  The ability to pseudo-type VSV with foreign glycoproteins also adds to the data 
that suggests the interaction between G, M, and skeletons is a non-specific interaction 
(184).  Although VSV has a non-specific G cytoplasmic tail interaction in assembly, the 
G cytoplasmic tail of rabies virus is important for incorporation into rabies virions (149).  
This observation suggests the interaction between the cytoplasmic tails of each virion’s G 
protein with their respective skeleton is different between these two viruses found in 
Rhabdoviridae.  Recently, it has been shown that G and N may interact and this 
interaction allows for the RNP to associate with the M protein at the budding sites (195). 
 
 
VSV Entry and Uncoating 
 
 
Entry of enveloped viruses into the host cell.  Virions must penetrate the host’s 
cellular membrane to release their genomes and proteins into the cytosol where they gain 
access to the host’s machinery to replicate.  In the case of enveloped viruses, this 
penetration into the host’s cytosol requires a membrane fusion event to take place, which 
is accomplished by a fusion protein on the viral surface.  The membrane that is penetrated 
in this case can either be the plasma membrane or the membrane of an intracellular 
organelle along an endocytic pathway. 
 
It is known that enveloped viruses like Sendai virus and HIV-I have pH-
independent fusion proteins and can therefore fuse on the surface of the cell (52, 141).  
The pH-independent nature of fusion for these virions and others like them leads one to 
assume that fusion only occurs at the plasma membrane but this is difficult to prove as 
these virus particles are continuously taken up by endocytosis as well. 
 
Overall a majority of enveloped virions enter the cell through the endocytic 
pathway, giving them the ability to move further into the cell.  This allows them to 
bypass potential barriers and a crowded cytosol (135) using the cytoskeletal machinery 
involved in endocytic vesicle movement (45) in order to penetrate the cell for replication.  
Virions that enter the cell along the endocytic pathway like VSV and influenza, use the 
decreasing pH of endocytic organelles as a trigger for fusion in order to penetrate the cell 
(207). 
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Uncoating of genomes after entry of enveloped viruses.  Virions entering a cell 
have highly condensed genomes protected by proteins.  Before these particles can 
replicate in a host cell, after fusion and entry, an uncoating event must occur.  This 
uncoating event is described as release of the viral genome in a form that is immediately 
ready for replication (DNA viruses), transcription ((-) RNA viruses), or translation ((+) 
RNA viruses).  Typically, uncoating involves the dissociation of the proteins condensing 
the genome.  Once the genome has uncoated replication of the virus can begin and this 
process is the opposite of what occurs to package the virus for release.  Here lies the 
dilemma for how a virus can accomplish these two distinct mechanisms for the same 
protein. 
 
Influenza virus is the best example of how a virus can accomplish this through 
virus-host interactions.  As influenza virus is taken into the cell by endocytosis, the virus 
encounters decreasing pH the further it is along the pathway.  The virus takes advantage 
of this pH decrease in another manner that is not linked with the pH-dependent fusion 
during entry.  Within its viral membrane there is an integral membrane protein called M2 
that acts as an ion channel that shuttles the protons in the endosome into the virus (110, 
169).  In turn the acidification within the virion facilitates the dissociation of the M1 
protein away from the viral RNPs of influenza virus (24, 222) resulting in enhanced 
uncoating.  This is a fascinating, yet simple approach for a virus to achieve the uncoating 
dilemma by taking advantage of the different environments during the entry pathway. 
 
 
VSV and the uncoating dilemma.  VSV faces the same intriguing question 
about what is responsible for the dissociation of M protein from RNPs.  Unlike influenza 
virus, VSV lacks an ion channel protein although previous studies have found at low pH 
spike proteins of enveloped viruses such as VSV, Sindbis virus, and Semliki Forest virus  
can make the viral envelope permeable to propidium iodide (101, 114).  Also, cells 
expressing these proteins on the cell surface show a pH-dependent permeability (101, 
114).  These observations coupled with the knowledge of how influenza virus uncoats 
would lead one to believe that protons may be able to cross the viral envelope and affect 
M in a manner similar to M1.  However, in vitro studies did not discover a pH effect on 
the M protein associated with skeletons (130).  Instead it was suggested that dissociation 
of M protein from skeletons occurs spontaneously as a result of the lack of M protein in 
the cytosol since it was observed that association and dissociation of M at physiological 
ionic strength with RNPs isolated from cells had characteristics of a dynamic reversible 
equilibrium (130).  The very idea that protons may cross the viral envelope is still an 
intriguing concept considering that there are at least two populations of M (membrane 
and RNP bound) within the virus.  The skeleton associated M has been investigated in 
previous studies but the effect of pH on M within the whole virion has not, which leads to 
an interesting aspect to examine, namely whether VSV may employ a similar strategy as 
influenza virus.  This strategy may be similar for many of the enveloped virions that use 
the endocytic pathway for entry. 
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M in VSV Assembly 
 
 
Budding of VSV progeny from host cells.  Enveloped, negative-strand RNA 
viruses have proteins with late domain motifs that are involved in recruiting the cellular 
vacuolar protein sorting machinery to bud progeny virions from the host cell.  Examples 
include the gag proteins of retroviruses (165), the Ebola virus VP40 protein (12), rabies 
virus M protein (80), and VSV M protein (80).  These proteins contain either PS/TAP or 
PPxY (PY) motifs that recruit WW containing ubiquitin ligases used in the cellular 
fission machinery and/or the ESCRT-I complex (78, 103, 194, 201).  VSV has both the 
PPPY and PSAP motifs at the N-terminus of M, where the PY motif has been shown to 
be important for budding activity (80, 91).  The PSAP motif has not been shown to have 
a major late domain role, but mutations in this region led to attenuation of virus both in 
vitro and in vivo (86). 
 
 
M protein and nucleocapsid condensation.  As discussed previously, the 
condensation of RNPs by M protein is a reversible process.  Despite the fact that the 
cytoplasm of VSV infected cells contains high concentrations of both intracellular RNPs 
and soluble M protein, the two do not colocalize with one another (133, 160).  The 
plasma membrane is where M and RNPs interact with each other, suggesting that 
condensation of RNPs does not begin until they associate with the membranes right 
before budding (146, 157).  Also, it has been proposed that an additional priming event is 
needed in order to initiate the assembly process and may involve specific M nucleation 
sites (67) or modification of the RNPs by viral or host factors (57, 130, 195).   
 
The exact location of M within virions is a controversial topic at this time.  The 
general consensus is that M binds to RNPs and condenses them into skeletons (44, 153, 
154).  Whether M is inside and/or outside the skeleton is still not clearly defined.  The 
traditional view point is that M acts as a bridge between the nucleocapsid and the viral 
membrane; putting it on the outside of the RNP (157, 162, 220, 221).  Another point of 
view is that M protein may form a rod-like scaffold around which the nucleocapsid is 
wound (10, 11).  A more detailed analysis of the virion’s structure is needed before one 
or both of these ideas are accepted.  It is clear though that there are two populations 
inside the virion, the membrane and RNP bound forms.  M protein has the ability to self-
associate: purified M protein was found to be a monomer in high ionic conditions 
(500mM NaCl) in the absence of detergent, and in aggregates in low ionic conditions 
(<200mM NaCl) (147).  This self-association under low salt conditions was reversible by 
treatment with Triton X-100 (147), suggesting that a hydrophobic interaction is involved 
along with electrostatic interactions seen under the different ionic strength conditions.  
Furthermore, nucleation sites have been implicated in the ability of M to self-associate, 
where the N terminus is important for the creation of these nucleation sites and an 
exposed loop in the C terminus is important for recruitment into these sites (65, 67).  
Biophysical studies and electron microscopy have shown the aggregates of M to be rod-
like in shape and to have similar striations like those found in skeletons (67).  Suggesting 
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that the aggregates have similar morphological features when compared to skeletons and 
that the exposed loop is important for the assembly of VSV. 
 
 
Self-association of VSV M protein.  The protease-sensitive exposed loop, 
located between amino acids 120-129, of the M protein has been implicated in virion 
assembly, specifically in regard to M self-association (66).  Cleavage of this loop with the 
protease thermolysin results in M that cannot self-associate.  In fact, M self-association 
was an obstacle in the crystallization of the protein.  It was found that cleavage by 
thermolysin prevented self-association and allowed diffractable crystals to form (66).  
This cleavage site was different from trypsin sites (loss of pleiomorphic N-terminus) on 
M and was found to be between amino acids 120-PAVLADQGQP-129 (65).  Full-length 
M (M), M cleaved by trypsin (Mt), and M cleaved by thermolysin (Mth) were studied and 
found to have a decrease in the ability to self-associate in the order M>Mt>Mth (65).  This 
exposed loop is also believed to be involved in association of matrix with the plasma 
membrane, which is where the matrix protein condenses the RNP into a skeleton (66, 
157).  The crystal structure of the Mth globular C-terminus revealed that there are seven β 
sheets that cover three core α helices like a “turtle shell” (66).  The loop is located on the 
exterior (thermolysin cleavage) between a large and small β sheet that leads to one of the 
core α helices (66).  Mutations in the loop at amino acids 121 to 124 have been studied 
and were found to have a minor effect on VSV assembly, and also infection of cells with 
this virus resulted in reduced viral protein synthesis at 6 to 8 hours post infection (35). 
 
 
VSV Cytopathogenicity and Methionine 51 of M 
 
 
Leader RNA transcripts.  VSV infection causes a range of cytopathic effects 
from the shut down of host protein synthesis to the rounding of the cell at later times post 
infection (138).  Two products involved in inhibition of protein and RNA synthesis were 
implicated in ultraviolet (UV) mapping experiments of which one was the leader RNA 
transcript (48, 71, 206).  The leader transcript is 45 nucleotides long and is transcribed 
from the 3’ end of VSV’s genome before viral mRNAs are made.  The role of the leader 
RNA transcript in RNA synthesis inhibition has been implicated by observations that 
revealed leader transcripts could be found in the nucleus of a host cell shortly after 
infection (108), that leader RNA could associate with La protein, a putative RNA 
polymerase III transcription factor (175), and that leader RNA could inhibit transcription 
of RNA by the RNA polymerase II and III enzymes in HeLa cell extracts (72, 73, 148).  
It must also be said that leader RNA on its own was shown to be insufficient to inhibit 
host transcription, where a host factor or viral protein(s) may be required for the 
inhibition (47, 170).    
 
 
Inhibition of host gene expression by M protein.  The viral protein required to 
inhibit host transcription was found to be M by in vitro and in vivo studies.  Within 
infected cells the M protein is found in the nucleus (133), and the expression of the 
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protein alone in the absence of other viral components results in the inhibition of host 
directed gene expression (14).  In fact, it is difficult to express M from vectors that rely 
on the host cell transcription machinery (16, 122).  Inhibition of transcription by M was 
shown to be very effective, where it reduced the amount of gene reporter expression by 
50% with 1,000 fold less protein present than the amount found in host cells between 4 
and 6 hours post infection (131).  M protein has been shown to reduce expression from 
the IFNβ promoter (55), which was correlated with inhibition of RNA transcription and 
protein translation (4).  The inhibition of transcription has been linked to interference 
with RNA polymerase II in a non-promoter-dependent manner and RNA polymerase III 
in a promoter-dependent manner (3).  It has also been shown that M interferes with 
transcription factor (TF) IID but most likely in an indirect manner as M could not 
interfere with TFIID in an RNA polymerase II in vitro transcription assay (218, 219). 
 
The inhibition of host gene expression was found to be genetically separable from 
the assembly functions of M.  In a study of the temperature-sensitive (ts) mutant tsO82, 
where M has a M51R mutation and is defective in its ability to inhibit host gene 
expression, it was shown that ts082 could rescue a group III M mutant tsO23 virus that is 
defective in assembly (15).  This separation of host gene expression inhibition and 
assembly activity was also shown by observing the MN1 deletion mutant, lacking amino 
acids 4-21 at the N-terminus, which was assembly defective but was still able to function 
in inhibition of gene expression (15). 
 
 
Inhibition of nucleocytoplasmic transport by M protein: implications for 
methionine 51.  The M protein has multiple cytopathic effects on the host cell and in 
addition to the inhibition of transcription it can inhibit nucleocytoplasmic transport of 
host mRNA when the protein is expressed in cells (168).  In Xenopus laevis oocytes, M 
inhibited the import of snRNPs and karyophillic proteins as well as export of snRNAs 
(60) and mRNAs but not tRNAs (168).  This block of transport was shown to inhibit 
snRNA processing and assembly within 1 hour of infection and may be the first 
cytopathic effect by VSV (60). 
 
The inhibition of nucleocytoplasmic transport by the M protein has been shown to 
be through the interaction with RaeI and the nucleoporin Nup98 at the nuclear pore 
complex (NPC) (53, 204).  The region on the M protein that is responsible for this 
interaction has been mapped to amino acids 51-59 with methionine 51 (M51) being the 
most important for colocalization to NPCs and inhibition of nucleocytoplasmic transport 
(168).  Recently, it was also shown that the VSV New Jersey M48 and M51 residues are 
important for inhibiting gene expression, suggesting that these may be involved in a 
similar mechanism for this M protein (104). 
 
The M51 residue and its role in nucleocytoplasmic transport inhibition has been 
put to the forefront of oncolytic therapy with VSV (50, 109, 127, 193).  It was shown that 
attenuated VSVs with a deletion or mutations at the M51 residue were able to exploit the 
inability of oncogenic cells to respond to interferon, leading to infection and oncolysis. 
While the cells cannot respond to interferon, they can make interferon and this leads to 
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protection of cells that can respond to interferon in vivo (192, 193).  This is the basis for 
oncolytic therapy at the present time and will be a part of the future of VSV as an 
oncolytic vector (8, 9, 36, 49, 62, 127, 156, 171, 188, 213, 214). 
 
 
Cell rounding: as a hallmark of VSV infection.  A characteristic of wild-type 
VSV infections is the loss of a cell’s normal morphology resulting in cells that become 
round (155, 217).  This ability to round the cells has been attributed to the M protein (16) 
and the sequential disassembly of the cytoskeleton (190).  It was also shown that M 
protein could co-immunoprecipitate with tubulin from infected cell extracts and that M 
could interact with polymerized and disassembled tubulin in vitro (150).  In these studies 
it was suggested that the highly basic N-terminus was important for this effect as 
proteolytically cleaved M did not associate with tubulin as well in vitro and this 
interaction was indicated through the acidic C-terminus of tubulin (150).  This suggestion 
does not correlate with data from cells expressing the deletion mutant MN1, which is 
missing amino acids 4-21 and therefore the highly basic region, which lost their 
morphology and became round (129). 
 
The tsO82 M51R mutation in M protein on the other hand affected the ability to 
cause the dissociation of the cytoskeleton in cells expressing that protein (129).  This 
observation correlates with data that suggested two additional translation products from 
the M gene, called M2 and M3, were important for the cell rounding phenotype of the M 
protein (92).  It was found that these products were the result of downstream methionines 
in the same open reading frame as full-length M, at methionines 33 and 51.  When these 
residues were mutated to alanines (M-33,51A) the translation of M2 and M3 was 
abolished and cell rounding was delayed without affecting virus assembly.  Transient 
expression of M2 and M3 was sufficient to cause cell rounding and expression of these 
proteins from a separate cistron in a virus that expressed M-33,51A restored cell 
rounding, suggesting these two translation products are required for cell rounding (92).  
These data taken together with the M51R M mutant data suggest that not only is the 
methionine 51 residue important for inhibition of nucleocytoplasmic transport but also as 
a start site for a polypeptide of M that contains amino acids 51-229.  One could imagine a 
scenario where this offers VSV an advantage of having different populations of M: (1) a 
population with the N-terminal amino acids important for membrane binding and 
budding activity that is used for assembly of progeny virions and (2) a population without 
those amino acids that cannot be sequestered to the cellular membranes as readily and 
therefore could interact with NPCs and cause other cytopathic effects.  Not only has this 
been shown for VSV Indiana M protein but it has recently been shown that methionines 
48 and 51 of the VSV New Jersey M protein have similar requirements for CPE (104). 
 
 
M protein and apoptosis.  It was found that VSV infection in HeLa cells resulted 
in fragmentation of chromosomal DNA into nucleosomal oligomers and in nuclear 
fragmentation, which are cell effects usually associated with apoptosis (107).  In fact, it 
was shown that expression of the M protein from mRNA within HeLa and BHK cells 
could induce apoptosis because the cells underwent morphological changes and caspase-3 
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was activated (106).  It was also suggested that the cell rounding ability of M was a result 
of apoptotic activity (105).  Comparison of wild-type M and the M51R mutant revealed 
that these proteins could induce apoptosis differently where wild-type used the 
mitochondrial induced pathway and was shown to be sensitive to over expression of Bcl-
2 (63).   In contrast, the M51R mutant could induce apoptosis through the death receptor 
pathway and required activation of caspase-8 (63) through PKR, Fas, and Daxx signaling 
(62). 
 
 
Enveloped RNA Viruses: Origins and M Proteins 
 
 
Origin and evolution of RNA viruses.  The origin of “the ancestor” nsRNA 
virus and the relationship between this ancestral virus and present day virions that are 
continually evolving is a topic that is not easily addressed.  Unlike the evolutionary study 
of animals and plants, there is no fossil record of their existence over billions of years.  
All that can be studied are the genomes and their products, the replication strategies, and 
host ranges of viruses to make any inference about where they may have originated in 
terms of evolution. Based on these observations viruses have been classified by either the 
International Committee on Taxonomy of Viruses (ICTV) or by the Baltimore 
classification system (7, 140). Evolution is a consequence of the reproductive success of 
individuals and their phenotypes that have an influence on the subsequent genotypes that 
occur from generation to generation.  Due to their self-replication and polymerase fidelity 
mutations can occur that increase the fitness of nsRNA viruses.  The escape from host 
antiviral responses by HIV-I (37) and changes in host range by influenza A (205) are a 
few of the examples of the evolution of some RNA viruses whether they be short or long 
term changes. 
 
 
M proteins of enveloped RNA viruses.  Enveloped RNA viruses use M proteins 
to condense RNPs and to link RNPs to the virus membrane.  In the case of retroviruses, 
which have a precursor gag polyprotein consisting of the matrix (MA), capsid (CA), and 
nucleocapsid (NC) proteins, the CA protein condenses the genome and the MA is 
responsible for RNP association with the virus membrane.  Though similar in function, 
the sequence homology of the M proteins from filo-, rhabdo-, myxo-, and paramyxovirus 
and retroviral MA do not show clear homology although the L domains of PS/TAP or PY 
motifs are similar in these proteins that function in budding of virions from host cells (40, 
79, 80, 119, 216).  Comparison of the structural homology has been examined by 
structural biologists in reviews of the literature between Ebola virus VP40, VSV M, and 
HIV MA and these were found to have no structural homology (200), but a comparison 
between influenza virus M1 and HIV MA and CA proteins revealed that the M1 protein 
may have a combination of the important structural assembly elements of the MA and 
CA proteins (77).  Taken together these observations show that trying to find the 
evolutionary link between proteins from RNA viruses is a complicated endeavor.  
Proteins that have the same function can just be a result of necessary functions needed to 
release protected genomes from cells so the virus has acquired (or evolved) a protein for 
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this function.  Alternatively, these proteins may have structures that have arisen for the 
functions suggesting modular evolution. 
 
 
Hypotheses 
 
 
Hypothesis 1.  Based on the literature discussed in this introduction, the first 
hypothesis investigated in this dissertation is that VSV uses host cell factors/processes for 
dissociation and distribution of the matrix protein during uncoating (Chapters 2 and 3).  
The areas of investigation for this hypothesis are indicated by (1) and (2) respectively, in 
Figure 1-3. 
 
 
Hypothesis 2.  The second hypothesis investigated is that the amino acid 
sequence of the exposed protease-sensitive loop of the M protein is important for VSV 
assembly (Chapter 4) at the site indicated by (3) in Figure 1-3. 
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Figure 1-3.  Hypotheses model. 
(1) Location within the VSV entry pathway where the question of what cellular factor is 
involved in uncoating will be addressed.  (2) After dissociation of M from RNPs what 
cellular processes are involved in M distribution?  (3) Location in assembly of VSV 
where the question of the amino acids in the protease-sensitive loop will be examined. 
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Chapter 2:  Analysis of Matrix Protein Distribution after 
Vesicular Stomatitis Virus Uncoating 
 
 
Introduction 
 
Entry of enveloped viruses through the clathrin-mediated endocytosis pathway 
generally occurs by attachment to the cell surface and uptake of virions in coated vesicles 
that are transported through the endosomal pathway to early or late endosomes.  At early 
or late endosomes there is a pH induced fusion of the endosomal and viral membrane, 
which results in virus uncoating and release of the genome (114, 136).  Vesicular 
stomatitis virus (VSV), a prototype enveloped, nonsegmented, negative-strand RNA virus 
in the family Rhabdoviridae, enters the host cell through this pH-dependent endocytic 
pathway (139).  VSV’s genome encodes five major viral proteins: the nucleocapsid 
protein (N), the phosphoprotein (P), the matrix protein (M), the glycoprotein (G), and the 
large polymerase protein (L).  The viral genome is encapsidated by the N protein and 
associates with the viral RNA-dependent RNA polymerase (complexes of L and P 
proteins), which together form the ribonucleoprotein (RNP) complex.  The M protein 
within virions is associated with RNPs in structures called skeletons (153, 154) and a 
separate membrane associated population of M anchors the skeletons to the viral 
membrane (31, 151), which has transmembrane G protein spikes that protrude from the 
membrane.  The G protein is responsible for attachment of virions and fusion of the 
endosomal and viral membranes (18, 82, 134, 161, 198, 211) and results in the transfer of 
the genome into the cytoplasm where VSV replication occurs following fusion (139).  
Either directly after or concomitant with membrane fusion, M protein dissociates from 
the RNP core which results in the decondensation of the skeleton (153, 154) and 
completes virus uncoating (174).  After uncoating, the decondensed RNP serves as a 
template for transcription of viral mRNAs by the packaged RNA-dependent RNA 
polymerase. 
 
Virus uncoating, defined as the dissociation of M from RNPs is an essential step 
which is required for a productive infection (130); without this occurrence it is thought 
that transcription of viral mRNAs will not proceed since it has been shown that 
transcription from RNPs is inhibited by M protein (32, 44, 212).  This essential step is 
also shared by another enveloped negative-strand virus, influenza, which requires 
removal of its matrix protein (M1) for a productive infection (102, 137).  To better 
understand this essential uncoating step, we wanted to develop a recombinant VSV 
(rVSV) that would allow us to visualize the release of M protein in live cells. 
 
Five different rVSVs encoding fluorescent M proteins were constructed for this 
study.  Three of these contained M fused to green fluorescent protein (GFP).  This 
strategy has been used to generate rVSVs that encoded fluorescent G (G-GFP) and P 
(PeGFP) proteins which were used to examine virus entry and assembly (41, 42).  In 
previous studies, GFP has been fused to M at the N and C termini to observe M protein 
expression, function, and localization in the absence of other viral proteins (69, 123, 168), 
but these chimeric proteins were not studied in the context of virus assembly.  Here we 
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fused GFP to the C-terminus of M (MFC) to avoid the important regions on the N-
terminus involved in membrane association (30, 31, 120, 217) and virus budding (80, 91).  
Unexpectedly, the M-GFP chimeras had reduced budding activity when compared to M 
wild-type (Mwt), and rVSVs that encoded MFCs as the sole M protein were unable to be 
recovered; however virus encoding Mwt and MFC as an additional gene between G and 
L (rVSV-M-MFC) was recovered, but the amount of MFC incorporated into virions was 
low and we were unable to detect the virus bound to cells by fluorescence microscopy. 
 
In an alternative approach we fused a tetracysteine (-CCRECC-) LumioTM tag to 
M and recovered infectious virus.  LumioTM technology has been used previously to 
study Ebola VP40 membrane localization (164) and to label human immunodeficiency 
virus-1 (HIV-1) integrase for live cell HIV-1 entry (5).  Using in vivo labeling with 
LumioTM Green and purification of labeled virus we visualized VSV entry and the 
subsequent fate of M-Lumio-Green in fixed and live cells. 
 
We show that after fusion of rVSV-M-Lumio-Green with endosomes, the bulk of 
M-Lumio-Green remains associated with recycling endosomes but some also localizes to 
the nuclear envelope.  The delivery of M-Lumio-Green to the nuclear envelope was not 
dependent on actin or tubulin suggesting this may occur by diffusion. Using confocal 
microscopy we observed that RNPs physically separated from M-Lumio-Green on the 
endosomal membrane and that the release of RNPs into the cytoplasm was also not 
dependent on microtubules.  We believe the release of RNPs seen after rVSV-M-Lumio-
Green virions have fused with endosomes is a measure of an uncoating event and 
therefore defines the start of a productive infection for rVSV virions. 
 
 
Materials and Methods 
 
 
Plasmid design and construction.  Construction of the cDNAs of MFC-II, -III, 
and -IV (MFC) illustrated in Figure 2-1A was accomplished using pBluescript(BS) MΦT 
(wild-type; Indiana) as a vector and overlapping PCR to fuse the N-terminus of GFP to 
the C-terminus of M.  Primers (GFP-M-C-Link-C, CEM 4, or 5) which had a 5’ NheI site 
followed by sequences encoding an 8 (-II), 15 (-III), or 20 (-IV) amino acid (Gly-Ser) 
linker that joined to the initiating methionine of GFP, were used together with a non-
coding primer (GFP-NdeI-NC) to amplify a PCR fragment that served as a link between 
M and GFP in a triple ligation of gel purified fragments. The M-GST cDNA was 
constructed by fusing the N-terminus of GST to the C-terminus of M using an 8 amino 
acid (Gly3-Ser)2 linker in a similar way but using the primer 5’GST-cod to join the linker 
to the initiating methionine of glutathione-S-transferase. 
 
pBS-M-Lumio was constructed by annealing two overlapping oligonucleotides 
that encoded the tetracysteine (*) LumioTM tag (Fig. 2-1B, amino acids 230-246) to the C-
terminus of M.  A coding and non-coding oligonucucleotide (CEM6 and CEM7) that 
encoded the amino acids in the tag were phosphorylated with T4 polynucleotide kinase 
 
 
Figure 2-1.  Schematic of fluorescent M proteins and rVSV genomes. 
(A) Depiction of the MFC protein and the organization of the rVSV-M-MFC genome.  (B) Illustration of the Lumio-M and M-Lumio 
proteins.  Amino acid positions are designated by numbers and the amino acid sequence of the LumioTM tag (gray box) at the C-
terminus is shown.  The Lumio-M protein contains an initiating methionine on the N-terminus of the Lumio-tag.  The cysteines that 
bind the biarsenic LumioTM reagent are denoted by * symbols.  The location of Lumio-M or M-Lumio in the viral genome is shown. 
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and were annealed to form a linker with NheI and EagI overhangs, and used to ligate into 
the vector pBS-M-Flag-C digested with NheI and EagI. 
 
The pBS-Lumio-M plasmid was constructed by using PCR amplification of pBS-
MΦT as a template with a primer containing KpnI and AscI restriction sites, a Kozak 
sequence (TTCATCATGG), and the sequence for the LumioTM tag at the 5’ end which 
overlapped with the first 24 bp of the coding sequence of M (CEM8) and a 3’ reverse T3 
primer.  The product was digested with KpnI and EagI, gel purified, and ligated into pBS-
MΦT digested with the same enzymes.  Sequences of constructed cDNAs were 
determined by the Molecular Resources Center at the University of Tennessee Health 
Sciences Center and no changes from predicted sequences were found. 
 
 
Generation of full-length VSV cDNAs encoding MFC, M-GST, M-Lumio, 
and Lumio-M.  The MFC, M-GST, M-Lumio, and Lumio-M chimera sequences were 
cloned into the polylinker (PL) of a modified version of the VSV anti-genome pΔM-PLF 
(91) except there was no GFP between the G and L coding regions.  The resulting 
plasmids were called pVSV-MFC-II, -III, -IV, pVSV-M-GST, pVSV-Lumio-M, and 
pVSV-Lumio-M. For rVSV plasmids encoding Mwt and the MFC chimeras together, the 
cDNAs for MFC-II, -III, and -IV were cloned into the polylinker of pVSV-GL-PL (92) 
located between the G and L genes. 
 
 
Recovery and characterization of recombinant VSV (rVSV).  Recombinant 
viruses were recovered using reverse genetics (116) with some modifications as 
described previously (91).  Single-step growth curves were performed by adsorbing virus 
to baby hamster kidney (BHK-21) cells in 35 mm plates at a multiplicity of infection 
(MOI) of 10 for 1 hour at 31oC while continually rocking.  The inoculum was removed, 
the cells were washed 4x with serum-free Dulbecco’s minimal Eagle’s medium (DMEM) 
to remove unbound virus, DMEM containing  5% fetal bovine serum (FBS) was added, 
and the cells were placed at 37oC.  Every two hours post infection (hpi) a 5% aliquot of 
media was collected, replaced with the same volume of fresh media, and then virus titers 
were determined in duplicate by plaque assay on BHK-21 cells. Growth curves were 
performed in triplicate for each virus. 
 
 
Transient expression of MFC, M-Lumio, and Lumio-M proteins.  BHK-21 
cells at ~90% confluency on glass cover slips in 35mm dishes, were infected with a 
modified vaccinia virus (vTF7-3) encoding T7 RNA polymerase (61) at MOI 5 for 1 hour 
at 31oC in SF-DMEM.  The inoculum was removed and the cells were transfected with 
5µg of pBS-MΦT (wild-type; Indiana), pBS-MFC-II, -III, or -IV, pBS-M-Lumio, or 
pBS-Lumio-M using 20 µl TransfectACE in SF-DMEM (180).  Five hours post 
transfection (p.t.) the transfection mix was removed and replaced with 5% FBS DMEM 
containing antibiotics (100U/ml streptomycin and penicillin), and 18 hours p.t. the cells 
were fixed and processed for immunofluorescence or were used in a budding assay as 
described below. 
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Immunofluorescence (IF) staining and confocal microscopy.  Cells either 
transiently expressing M proteins from plasmids or infected with rVSV were washed 
twice with phosphate-buffered saline (PBS) and then fixed for 15 minutes with 3% 
paraformaldehyde (PFA) in PBS at room temperature (r.t.).  The fix solution was then 
removed and the cells washed twice with PBS containing 10 mM Glycine and 0.05% 
sodium azide (PBS-Glycine), and then permeabilized with 1% Triton X-100 in PBS-
glycine at r.t. for 1 minute.  After permeabilization, the cells were washed twice with 
PBS-Glycine and then stained for; M protein using an anti-M monoclonal antibody (mAb 
23H12) conjugated to rhodamine, VSV N protein using anti-N mAb 10G4 conjugated to 
rhodamine, Nup62 using anti-Nup62 mAb (# 610497, BD Biosciences), mannose 6 
phosphate receptor (M-6-P-R) using anti-M-6-P-R mAb (# MA1-066, Affinity 
BioReagents), LAMP-1 using anti-LAMP-1 mAb (Developmental Studies Hybridoma 
Bank at the University of Iowa), or microtubules using anti-α tubulin mAb (# A-11126, 
Molecular Probes).  The unconjugated primary antibodies were detected with a goat anti-
mouse secondary antibody conjugated to rhodamine (Jackson Research Laboratories) or 
for anti-Nup62 we used Zenon Goat anti-mouse IgG2b Alexa Fluor 647 (# A-21242 
Invitrogen; Molecular Probes).  Phalloidin conjugated to Texas Red-X (Invitrogen; 
Molecular Probes) was used to stain actin.  The distribution of the indicated proteins was 
examined using laser scanning confocal microscopy (Zeiss LSM 510 AIM version 3.2 
software).  Optical slices of 1 µm were captured using 488nm, 543nm, and 633nm laser 
excitation.  Quantification for colocalization of M and N protein was accomplished using 
the “Profile” function of the Zeiss LSM software by counting the number of N protein 
foci that colocalized with M in a total of 50 cells from three different experiments. 
 
 
Budding assays.  Cells transiently expressing the indicated M protein were 
washed twice with methionine-free, SF-DMEM and then incubated in this media for 15 
minutes to deplete the intracellular methionine pools at 5 hours p.t.  After depletion, a 
media composed of 1 part 5% FBS DMEM to 9 parts methionine-free media and 
supplemented with 50 µCi of 35S-Methionine (Met) Express Protein Labeling Mix 
(Perkin-Elmer) per ml was added and 18 hours later media and cells were collected 
separately and processed for immunoprecipitation (IP).   
 
The media were centrifuged at 170 x g for 10 minutes to remove dislodged cells 
and the supernatant was placed on ice after addition of 200U of aprotonin (U.S. 
Biochemicals).  The supernatant was made to 50mM Tris-HCl, 150mM NaCl, 0.1% NP-
40, 1mM EDTA, 20mM NaN3, 0.3% SDS, and radio-labeled M proteins were 
immunoprecipitated with M mAb (23H12) overnight at 4oC and retrieved using 
Pansorbin (#507861, CALBIOCHEM). 
 
Cell extracts were prepared by washing the cells twice with PBS and then lysing 
with 800 µl of detergent solution (10 mM Tris-HCl [pH 7.4], 66 mM EDTA, 0.4% 
sodium deoxycholate, 1% Triton X-100, 0.05% NaN3) containing 200U/ml of aprotonin 
for 5 minutes at r.t. on a rocker.  The cell extract was collected, nuclei and insoluble 
material removed by centrifugation at 10,000 x g for 5 minutes and a 200 µl aliquot of 
the cell extract was made to 0.3% SDS and immunoprecipitated with M mAb (23H12) 
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overnight at 4oC followed by Pansorbin retrieval.  One-quarter of the radio-labeled M 
proteins in the cell extract were compared to the amount released into the supernatant by 
SDS polyacrylamide gel electrophoresis (PAGE) on a 9% polyacrylamide gel and 
visualized by fluorography. 
 
 
Immunoblot analysis of rVSV-wt and rVSV-M-MFC virions.  To detect the 
presence and location of M-wt and MFC within virions, 1 µg of protein (~1 x 107 PFU) 
from purified rVSV-wt or rVSV-M-MFC was solubilized by 0.1% Triton X-100 TN 
Buffer (10 mM Tris-HCl [pH 8.0], 150 mM NaCl) in a total volume of 1 ml or left 
untreated. One ml of each solubilized virus preparation was then ultracentrifuged over 3.5 
ml of a 20% sucrose cushion (10 mM Tris-HCl [pH 8.0], 150 mM NaCl) at 45,000 rpm 
for 35 minutes in an AH-650 swinging bucket rotor (Sorvall).  After centrifugation 1 ml 
of the supernatant was collected and the proteins in this fraction were precipitated by 
adding trichloroacetic acid (TCA) to a final concentration of 10%.  Viral proteins in the 
pellet (RNP fraction) and the supernatant were separated by SDS-PAGE on a 10% 
polyacrylamide gel and then transferred to a polyvinylidene fluoride (PVDF) 
microporous membrane (Immobilon-P; Millipore).  Monoclonal antibodies to M (23H12) 
and GFP (# MMS-118R Covance) were used to detect each protein followed by addition 
of a goat anti-mouse antibody tagged with horseradish peroxidase (Jackson Research 
Laboratories).  Proteins were located using a chemiluminescence kit (Immobilon 
Western; Millipore) according to the manufacturer’s instructions. 
 
 
LumioTM Green labeling and quantification of rVSV.  BHK-21 cells on 100 
mm plates at ~95% confluency were infected with rVSV-wt, rVSV-M-Lumio, or ΔG-M-
Lumio at MOI 1.  The inoculum was removed after 1 hour, the cells were washed two 
times with SF-DMEM and 10 ml of 5% FBS DMEM was added.  At 4 hpi the cells were 
washed twice with reduced-serum Opti-MEM I media (GIBCO) and replaced with 10 ml 
of Opti-MEM I containing 200 nM LumioTM Green (Invitrogen).  Eighteen hpi the 
supernatant was collected and labeled virus was concentrated by centrifugation over a 
20% sucrose cushion at 38,000 rpm in an SW41 swinging bucket rotor (Beckman) for 45 
minutes.  The viral pellet was resuspended on ice in 1 ml of 10% sucrose TN buffer.  
Residual, unbound LumioTM Green reagent was removed from the resuspended virus 
preparation by adding 100 µl aliquots to Sephadex G-50 (Fine) columns (Roche).  The 
void volume containing the virus was collected and stored at -80oC except for ΔG virions 
which were used for experiments on the same day of preparation.  Titers were determined 
by standard plaque assay on BHK-21 cells and protein concentration was determined by a 
BCA protein assay (Pierce) according to the manufacturer’s directions. 
 
The amount of fluorescence in the virus suspensions was determined by adding 
one microgram of viral protein to a cuvette that contained 3 ml of HMTN buffer (10 mM 
HEPES, 10 mM MES, 10 mM Tris-HCl [pH 8.0], 150 mM NaCl) using a Perkin-Elmer 
Luminescence Spectrometer (LS 50B).   Protein-specific fluorescence was examined by 
dissociating virus in SDS-PAGE sample buffer containing one-tenth the normal 
concentration of β-mercaptoethanol. Viral proteins were resolved on an SDS-10% 
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polyacrylamide gel and the gel was analyzed for fluorescent protein bands using a 
STORM 860 fluorescence imager (480 nm) and Imagequant software (Molecular 
Dynamics).  The same gel that was scanned for fluorescence was processed for 
immunoblot analysis using the anti-M antibody (23H12) and proteins were visualized as 
described above. 
 
 
Live-cell synchronized entry assay.  BHK-21 cells plated onto 35 mm glass 
bottomed culture dishes (MatTek Corporation) at 90% confluency were washed twice 
with 2ml of ice-cold Opti-MEM I and then placed at 4oC for 10 minutes.  Lumio-labeled 
virus (MOI 50) and human transferrin conjugated to Texas Red (50 µg) were adsorbed 
for 90 minutes in 100 µl ice-cold Opti-MEM I with rocking every 15 minutes at 4oC.  To 
initiate entry, the ice-cold inoculum was replaced with Opti-MEM pre-warmed to 37oC 
and the cells were observed by laser scanning confocal microscopy on a heated stage set 
to 37oC and equipped with an objective heating collar using 488nm and 543nm laser 
excitation with identical offset, gain and detector settings for each time point.  The non-
entry time point (t-0) was examined following addition of 2 ml of ice-cold Opti-MEM I 
on a stage at ambient temperature.  To reduce problems of sample photobleaching, 
separate plates were examined for each of the time points (t-10, t-15, t-20, t-25, and t-30). 
 
 
Synchronized fusion assay.  To prevent the acidification of endosomes and 
synchronize fusion of virions with endosomal membranes we used the lysosomotropic 
reagent NH4Cl as described previously (174) with some modifications.  BHK-21 cells on 
coverslips were washed twice with PBS and then washed twice with PBS containing 
100mM NH4Cl.  Viruses (MOI 50-100) either with or without 50 µg of transferrin-TR 
were adsorbed in SF-DMEM containing 100mM NH4Cl for 60 or 90 minutes.  After 
adsorption the cells were washed with PBS four times to remove the NH4Cl and were 
either fixed with 3% PFA (t-0), or 2 ml of SF-DMEM at 370C containing 10μg/ml 
cycloheximide was added for 60 minutes (t-60) and then fixed.  Synchronized fusion 
assays using the cytoskeletal inhibitors cytochalasin D or nocodazole were performed as 
above, except virus was adsorbed for 60 minutes in media with 100mM NH4Cl and the 
medium was replaced with SF-DMEM containing 10μM of the inhibitor and 100mM 
NH4Cl and incubated for 30 minutes.  The NH4Cl was then washed out as described 
above but the cytoskeletal inhibitors remained for 60 or 120 minutes post lysosomotropic 
washout (t-60 or 120) and the cells were fixed with 3% PFA and prepared for IF. 
 
 
Results 
 
 
Recovery and characterization of recombinant VSV encoding fluorescent M 
proteins.  To investigate virus uncoating and the fate of released M protein we 
constructed two different types of M proteins with fluorescent tags.  The first type 
consisted of green fluorescent protein (GFP) fused to the C-terminus of M (Fig. 2-1A, 
MFC).  Three different MFC constructs were generated with linkers of 8 (Gly3-Ser)2 
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(MFC-II), 15 (Gly4-Ser)3 (MFC-III), and 20 (Gly4-Ser)4 (MFC-IV) amino acids.  
Previously others had reported the construction of M-GFP fusion proteins with GFP 
fused at either the N- (69, 168, 204) or C-terminus (123) of M, but none of these 
contained a linker separating M and GFP, which we reasoned may be important for 
retaining the assembly function of M protein.  We chose to fuse GFP at the C-terminus to 
minimize interference with membrane association, which maps to the N-terminus of M 
(30, 31).  All three MFC proteins had identical intracellular distribution patterns when 
examined by immunofluorescence microscopy (IF) which was indistinguishable from M 
wild-type (wt) distribution (Fig. 2-2A). 
 
To determine if the three MFC constructs retained the ability to bud vesicles when 
expressed in cells (97) the amount of M released into the supernatant was examined.  
Despite the normal intracellular distribution of the three MFC proteins, there was a 
significant reduction in the amount of 35S-methionine labeled protein in supernatants 
from cells expressing the MFCs (MFC-III shown) compared to cells expressing Mwt 
(Fig. 2-2B lanes 3 and 2, respectively).  To determine if the reduced budding activity was 
due to a large C-terminal extension or was a specific GFP effect on budding activity, we 
fused glutathione-S-transferase (GST) to the C-terminus of M (M-GST).  Similar to the 
results with the MFC proteins, we observed a large reduction in budding activity (Fig. 2-
2B lane 4) even though there was no difference in cellular distribution of M-GST when 
compared to Mwt (data not shown). 
 
The low level budding activity of MFC and M-GST suggested that these proteins 
might not be able to support virus assembly.  Indeed, multiple attempts to recover rVSV 
expressing any of the three MFC proteins or M-GST as the sole M protein were 
unsuccessful (n = 6 per construct).  However, we did recover rVSVs that expressed both 
Mwt and the MFC proteins (rVSV-M-MFC, -II, -III, and -IV) from the same genome 
(Fig. 2-1A).  Characterization of these viruses showed that the growth kinetics were 
similar to rVSV-wt (Fig. 2-2C, rVSV-M-MFC-III shown), however it was found that 
MFC-III was incorporated at only 5% when compared to the amount of Mwt in rVSV-M-
MFC-III virions (Fig. 2-2D lane 4).  When virions were solubilized with Triton X-100 
and the RNP and envelope fractions examined, MFC-III was found mainly in the RNP 
pellet fraction (Fig. 2-2D lanes 5 and 9).  This result was unexpected since MFC-III was 
seen at the plasma membrane of cells infected with rVSV-M-MFC-III (Fig. 2-2E, 
arrows).  To determine if the small amount of MFC-III incorporated into virions was 
enough to detect in an uncoating assay, purified virus was bound to cells in the cold at a 
multiplicity of 100.  Cells were washed to remove unbound virus, fixed with 
paraformaldehyde and then examined by fluorescence microscopy.  Although virions 
could be detected when the fixed cells were permeabilized and probed with an M 
antibody, no GFP signal could be detected (data not shown).  Considering the low 
amount of MFC incorporation and lack of GFP signal when virions were bound to cells, 
it was necessary to use an alternative strategy to make rVSV with fluorescent M protein. 
 
The second type of fluorescent M protein we generated utilized LumioTM 
technology, in which a tetracysteine (-CCRECC-) LumioTM tag (Fig. 2-1B) was fused to 
the N or C-terminus of M (Lumio-M and M-Lumio, respectively).  To assess the cellular  
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Figure 2-2.  Characterization of the MFC protein and rVSV-M-MFC virions. 
(A) Laser scanning confocal microscopy of GFP, M-wt (Wt), and MFC-III expressed in 
BHK-21 cells.  Images are from 1 µm optical sections near the center of the cell where 
GFP was detected using laser excitation at 488nm and M by staining with a M mAb 
conjugated to rhodamine using 543nm excitation.  (B) M protein budding assay. Cell 
extracts and supernatants from cells infected with vTF7-3 alone (lane 1), or expressing 
Mwt (lane 2), MFC-III (lane 3), or M-GST (lane 4) were immunoprecipitated with M 
mAb after a 16 hour 35S-methionine labeling and examined by SDS-PAGE.  (C) Growth 
kinetics of rVSV-M-MFC and rVSV-wt.  Aliquots of media were collected at the 
indicated times post infection and titers were determined by plaque assay on BHK-21 
cells.  (D) Immunoblots of purified rVSV-wt (Wt) and rVSV-M-MFC (M-MFC) virus 
(lanes 1 and 4) using a monoclonal anti-M antibody, or RNP (lanes 2 and 7, lanes 5 and 
9) and TCA precipitated supernatants (lanes 3 and 8, lanes 6 and 10), after Triton X-100 
solubilization of virus and ultracentrifugation over a 20% sucrose cushion, using anti-M 
and anti-GFP monoclonal antibodies.  (E) Localization of MFC in BHK-21 cells infected 
with rVSV-M-MFC observed by confocal microscopy using laser excitation at 488nm at 
8 hours post infection.  Arrows show MFC associating with the plasma membrane of 
cells. 
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distribution and assembly function of these tagged proteins we compared them to M-wt 
by IF (Fig. 2-3A) and in a budding assay (Fig. 2-3B).  There was no discernable 
difference between the distributions of the M proteins as they all were located in the 
nucleus, were cytosolic, and localized to the plasma membrane (Fig. 2-3A).  When 
examined for budding activity, the N-terminally tagged Lumio-M showed a reduction in 
the amount of protein released from cells (Fig. 2-3B lane 4) although not to the extent of 
the MFC protein (Fig. 2-2B lane 3).  The C-terminally tagged M-Lumio on the other 
hand had wild-type budding activity (Fig 2-3B lane 6). 
 
To determine if Lumio-M or M-Lumio could support virus assembly we replaced 
the Mwt gene with the Lumio tagged versions in the viral genome (Fig. 2-1B).  Both 
viruses were easily recovered demonstrating that M proteins with small N or C terminal 
tags are functional for virus replication and assembly.  However, there was a growth 
defect observed for the N-terminally tagged Lumio-M virus whereas the growth kinetics 
of the virus with the C-terminally tagged M-Lumio virus was similar to rVSV-wt (Fig. 2-
3C).  Because the C-terminally tagged M-Lumio virus had growth properties 
indistinguishable from rVSV-wt we used the rVSV-M-Lumio construct to make 
fluorescent rVSV and for the uncoating studies described below. 
 
 
Fluorescent labeling of rVSV-M-Lumio.  LumioTM Green is a small (MW 
664.5), membrane permeable fluorophore which fluoresces green when covalently bound 
to the thiol pairs in the LumioTM tag (Fig. 2-1B, *) (2, 64, 70) .  To fluorescently label the 
rVSV-M-Lumio virus, we initially mixed purified virus with the LumioTM Green reagent 
similar to that described by others to label HIV virions encoding a Lumio-tagged 
integrase protein (5).  However, in our case no labeling occurred suggesting that the 
LumioTM tag was not available, or incapable of interacting with the fluorophore within 
virions.  We reasoned that the LumioTM tag may be more accessible for labeling within 
cells before assembly into M-Lumio virions, therefore we added LumioTM Green to the 
media of cells infected with rVSV-M-Lumio at 5 hours post infection (hpi).  The 
fluorophore containing media was removed one hour later and the cells were examined 
by IF (Fig. 2-4A).  We observed that the M-Lumio protein bound the fluorophore and the 
labeling colocalized with M protein staining (Fig. 2-4A, merge).  To produce fluorescent 
virus, the fluorophore was added to infected cells at 4 hpi and the virus in the media was 
harvested at 18 hpi.  The labeled virus (rVSV-M-Lumio-Green) was concentrated by 
ultracentrifugation through a sucrose cushion, resuspended in Tris-saline sucrose, and 
passed through Sephadex G-50 columns to separate labeled virions from residual free 
LumioTM reagent.  The purified virions were titered and the amount of fluorescence 
determined using a fluorometer.  To examine relative infectivity of the labeled rVSV-M-
Lumio-Green to a similarly prepared batch of rVSV-wt, we compared the protein profiles 
from 1x107 PFU of rVSV-wt and rVSV-M-Lumio-Green after electrophoresis on SDS-
polyacrylamide gels (Fig. 2-4B, left-hand gel).  The slightly slower migration of M-
Lumio compared to Mwt is due to the additional 17 amino acids of the LumioTM tag.  
Coomassie-blue staining indicated the two virus preparations had similar amounts of 
protein, but the rVSV-M-Lumio-Green had a 60-fold higher fluorescence signal than 
rVSV-wt virus.  To determine whether the fluorescent signal from the virions was due to 
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Figure 2-3.  Characterization of Lumio-M and M-Lumio and rVSV-M-
Lumio/(Lumio-M) virions. 
(A) Laser scanning confocal microscopy of M proteins expressed in BHK-21 cells and 
stained with monoclonal anti-M antibody conjugated to rhodamine.  (B) M protein 
budding assay.  Cell extracts (lanes 1, 3, and 5) and supernatants (lanes 2, 4, and 6) from 
cells expressing Mwt, Lumio-M, and M-Lumio after a 16 hour 35S-methionine labeling, 
immunoprecipitation with M mAb, and analysis by SDS-PAGE.  (C) One-step growth 
curve of rVSV-wt, rVSV-Lumio-M, and rVSV-M-Lumio. 
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Figure 2-4.  Labeling of rVSV-M-Lumio with LumioTM Green. 
(A) Laser scanning confocal microscopy of BHK-21 cells infected with rVSV-M-Lumio 
and labeled with LumioTM Green reagent for 1 hour at 6 hours post infection.  (B) SDS-
PAGE analysis of 107 PFU rVSV-M-Lumio-Green and rVSV-wt virions. The left-hand 
gel is stained with Coomassie blue.  The relative fluorescence signal/µg is shown below 
each lane.  The center gel is an immunoblot for M (anti-M, lanes 1 and 2), and the right-
hand gel (lanes 3 and 4) was visualized by excitation at 480nm on a STORM 
phosphorimager.  Lanes 1 and 3 contain rVSV-M-Lumio and lanes 2 and 4 contain 
rVSV-wt.  The anti-M reactive and fluorescent bands at approximately 56 KDa are likely 
artificially induced M-Lumio dimers formed as a result of the reduced concentration of β-
mercaptoethanol used in the sample buffer (see Methods for details). 
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specific binding of the LumioTM reagent to the M-Lumio protein, we used a STORM 
fluorescence imager (Molecular Dynamics) to visualize fluorescent proteins from 
purified virus after separation by SDS-PAGE.  Fluorescent protein bands were only 
observed with the rVSV-M-Lumio virus and the bands that corresponded to fluorescent 
M-Lumio protein were also detected in an immunoblot using an M-specific antibody 
(Fig. 2-4B lanes 1 and 3, respectively).  A higher molecular weight band was seen also in 
the M-Lumio lanes by fluorescence and immunoblot analysis.  This band corresponded to 
an M-Lumio dimer and was the result of two conditions: i) the reduced amount of β-
mercaptoethanol in the protein sample buffer, which was required to retain the LumioTM 
Green on the M-Lumio protein since increased reducing conditions results in the loss of 
Lumio-Green binding (data not shown); and ii) the addition of four cysteines to M (wild-
type has one cysteine at residue 135).  Overall, these data demonstrated that rVSV-M-
Lumio-Green was specifically labeled on the M protein and therefore should be useful to 
examine virus uncoating and fate of M-Lumio-Green within cells.    
 
 
Live-cell entry of rVSV-M-Lumio-Green.  To follow the entry of rVSV-M-
Lumio-Green virions into live cells, we adsorbed the virus (MOI 50) at 4oC for 90 
minutes to prevent endocytosis of virions, and then initiated their entry by endocytosis 
after addition of media at 37oC.  Transferrin conjugated to Texas Red (transferrin-TR) 
was used as an early and recycling endosomal marker during endocytosis of rVSV-M-
Lumio-Green and both reagents were followed in 5 minute intervals over a 30 minute 
time span, post addition of warm media (Fig. 2-5).  Images for each time point were 
acquired using identical detector settings to allow changes in fluorescence intensity to be 
quantified.  Figure 2-5 shows representative images of rVSV-M-Lumio-Green and 
transferrin-TR at t-0 (top panels), t-5 (middle panels), and t-20 (bottom panels).  At t-0, 
rVSV-M-Lumio-Green and transferrin-TR were bound to the plasma membrane and 
showed some colocalization.  At t-5 (Fig. 2-5, t-5) both markers were internalized, 
presumably in early endosomes.  At t-20 (Fig. 2-5, t-20), the bulk of M-Lumio-Green 
remained associated with perinuclear endosomes that colocalized with transferrin-TR 
(Fig. 2-5, t-20 merge), while a fraction of M-Lumio-Green was found at what appeared to 
be the nuclear envelope (Fig. 2-5, t-20 arrows).  M-Lumio-Green could be detected on 
the nuclear envelope as early as t-10 (data not shown), with increasing intensity up to t-
20, but there was no apparent gain in intensity of M-Lumio-Green fluorescence at the 
nuclear envelope after 20 minutes post-entry.  At no time did we observe transferrin-TR 
associated with the nuclear envelope. 
 
 
Synchronized fusion assay with rVSV-M-Lumio-Green.  To examine the role 
of new viral protein synthesis on the distribution of M-Lumio-Green after uncoating, we 
synchronized viral fusion in the presence of cycloheximide as was done in a previous 
study (174) with some modifications.  rVSV-M-Lumio-Green virions (MOI 50) were 
adsorbed to cells in the presence of NH4Cl to prevent acidification of endosomes and 
thereby inhibiting fusion of endocytosed virions (82, 174).  The inoculum and the 
lysosomotropic agent were removed, the cells washed 4 times, and media containing 
cycloheximide was added.  Cells were then fixed at varying times post NH4Cl removal, 
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Figure 2-5.  Synchronized entry assay with rVSV-M-Lumio-Green. 
Cells were inoculated with rVSV-M-Lumio-Green and transferrin-TR at 4oC for 90 
minutes, and either fixed immediately with ice-cold 3% paraformaldehyde (t-0) or were 
quickly warmed by the addition of 37oC media and examined by laser scanning confocal 
microscopy.  Images were collected every 5 minutes for 20 minutes using separate 35mm 
glass bottomed dishes for each time point to reduce loss of signal by photobleaching.  
(Top panels) Representative images of M-Lumio-Green and transferrin-TR at t-0 where 
cells were fixed at 4oC, * represents the center of a cell.  (Middle panels) Images 
collected at 5 minutes (t-5) post addition of warm media.  (Bottom panels) Images taken 
at 20 minutes (t-20) after warm-up.  Note the localization of M-Lumio-Green at the 
nuclear envelope (arrows) and in perinuclear endosomes that colocalizes with transferrin.  
Magnification 100X.
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stained with Nup62 antibody which binds to the nuclear pore complex (NPC) on the 
nuclear envelope, and with an M mAb, and observed by IF.  At t-0, rVSV-M-Lumio-
Green particles were in peripheral endosomes, similar to that found at the t-5 time point 
in the live-cell synchronized entry assay (Fig. 2-6, t-0).  At t-60, the bulk of M-Lumio-
Green was found in perinuclear endosomes (Fig. 2-6, t-60) and at the nuclear envelope 
(arrows).  Similar results were observed for rVSV-wt infected cells that were stained 
using the M mAb (data not shown) except nuclear envelope staining was not detected by 
the M mAb in either case (Fig. 2-6, t-60 center image) as this antibody binds to the site 
on M required to bind at the NPC (168).  Delivery of M-Lumio-Green to the nuclear 
envelope was confirmed by colocalization with the nucleopore protein Nup62 (Fig. 2-6, t-
60 merge).  These data showed that after NH4Cl washout M-Lumio-Green localized to 
the nuclear envelope in the absence of new protein synthesis and therefore represents M 
protein that is released into the cytoplasm and trafficked to the nucleus after uncoating. 
 
 
The perinuclear endosomes associated with M-Lumio-Green colocalize with 
transferrin-TR.  M-Lumio-Green distribution was perinuclear by 15 to 20 minutes post 
infection during synchronized entry of virus and at time points past t-20 (data not shown) 
of the synchronized fusion assay.  To determine the identity of these perinuclear 
structures, we used markers that corresponded to lysosomes (LAMP-1), late 
endosomes/lysosomes (Mannose-6-Phosphate receptor, M-6-P-R), and early/recycling 
endosomes (transferrin-TR).  We performed synchronized fusion assays with rVSV-M-
Lumio-Green, as described above, and used monoclonal antibodies to label the cells for 
LAMP-1 (Fig. 2-7A) and M-6-P-R (Fig. 2-7B), or visualized directly for transferrin-TR 
(Fig. 2-7C).  While some M-Lumio-Green colocalized with LAMP-1 (Fig. 2-7A) and M-
6-P-R (Fig. 2-7B) the majority of M-Lumio-Green colocalized with transferrin-TR (Fig. 
2-7C).  When images of the transferrin-TR endosomes that colocalized with M-Lumio-
Green were magnified (500X) the M-Lumio-Green was not evenly distributed throughout 
the endosome, but instead appeared to be located on one side of the endosome (Fig. 2-7D 
arrows).  A similar distribution of M-Lumio-Green and transferrin-TR was observed for 
images from the t-20 time point for synchronized entry (Fig. 2-5, t-20), which suggested 
the results seen in figure 2-7C were not an artifact of lysosomotropic reagent treatment.  
In contrast to the asymmetric distribution of rVSV-M-Lumio-Green in endosomes at t-60, 
internalized ΔG-rVSV-M-Lumio-Green virions, which lack G protein and therefore 
cannot fuse with the endosomal membrane, had a more diffuse distribution within the 
transferrin-TR positive endosomes (Fig. 2-7E), suggesting the asymmetric localization of 
M-Lumio-Green may represent virus that has fused and released its cargo.  These data 
indicate that even after 60 minutes most of the virus is not trafficked to late endosomes 
and lysosomes, but remains in compartments that are thought to be the primary site of 
virus uncoating. 
 
 
Trafficking of M-Lumio-Green to perinuclear endosomes and the nuclear 
envelope does not require actin or tubulin.  To determine whether or not actin and 
tubulin were required for delivery of M-Lumio-Green to the perinuclear endosomes at t-
60 or were required for delivery of M-Lumio-Green to the nuclear envelope, we treated  
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Figure 2-6.  Synchronized fusion assay with rVSV-M-Lumio-Green. 
BHK cells were inoculated with rVSV-M-Lumio-Green at MOI 50 in the presence of 
NH4Cl for 90 minutes to allow accumulation of virus in early endosomes.  Entry was 
initiated by incubation in media without NH4Cl, but containing cycloheximide.  Cells 
were fixed at t-0 (top panels) and t-60 (bottom panels), stained for M protein using a 
rhodamine conjugated anti-M mAb (red) and Nup62 labeled with Alexa 647 (blue), and 
examined by laser scanning confocal microscopy.  Arrows indicate the localization of M-
Lumio-Green at the nuclear envelope.  Note the M mAb does not detect M protein 
localized to the nuclear envelope.  Magnification 200X. 
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Figure 2-7.  Identification of perinuclear structures associated with M-Lumio-Green 
post fusion. 
A synchronized fusion assay was performed as described for figure 2-6.  Cells were fixed 
at t-60 then stained for (A) LAMP1, (B) Mannose-6-Phosphate Receptor, or (C) 
Transferrin-Texas Red and examined by confocal microscopy at 100X magnification.  
(D) is at 500X magnification of perinuclear vesicles containing M-Lumio-Green and 
transferrin-TR.  Arrows indicate an asymmetric distribution of M-Lumio-Green within 
transferrin-TR positive endosomes.  (E) 500X magnification image of ΔG-rVSV-M-
Lumio-Green inoculated cells showing transferrin-TR positive endosomes with a uniform 
distribution of M-Lumio-Green within endosomes. 
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cells with the cytoskeletal inhibitors cytochalasin D or nocodazole in a modified 
synchronized fusion assay.  Cells were inoculated with virions in the presence of NH4Cl 
for 60 minutes, and then the cytoskeletal inhibitors were added for the last 30 minutes of 
a 90 minute incubation.  After the 90 minutes of accumulation in early endosomes, the 
cells were washed with media that either did or did not contain the cytoskeletal inhibitors, 
and that also contained cycloheximide.  At t-60 the cells were fixed and stained for 
filamentous actin, using Texas Red-X phalloidin (Fig. 2-8) or for tubulin (Fig. 2-9).  
Either in the absence (Fig. 2-8, top panels) or presence of cytochalasin D (Fig. 2-8, 
bottom panels) after NH4Cl wash out M-Lumio-Green was found in perinuclear 
endosomes and at the nuclear envelope (Fig. 2-8, arrows).  When cells were treated with 
nocodazole to determine the involvement of microtubules in M-Lumio-Green distribution 
to the perinuclear region and nuclear envelope, we observed a reduction in the tight 
perinuclear localization of endosomes containing M-Lumio-Green (Fig. 2-9, top versus 
bottom panels), but the treatment did not prevent the association of M-Lumio-Green with 
the nuclear envelope (Fig.2-9, arrows bottom panels).  These results suggest that delivery 
of M-Lumio-Green to the nuclear envelope does not require intact actin or microtubules. 
 
 
Decrease in colocalization of M-Lumio-Green and N correlates with 
productive infection and does not require tubulin.  To determine if the M-Lumio-
Green nuclear envelope distribution was a result of uncoating, we assessed whether or not 
we could detect M-Lumio-Green physically separating from nucleocapsids by observing 
a decrease in colocalization of M-Lumio-Green and N using N mAb conjugated to 
rhodamine in the presence of nocodazole and cycloheximide.  rVSV-M-Lumio-Green 
(MOI 100) was endocytosed into cells in the presence of NH4Cl and nocodazole and the 
cells were observed at t-0 (Fig. 2-10A) and t-120 post NH4Cl washout, either in the 
presence of nocodazole and cycloheximide (Fig. 2-10B), or in media that contained only 
nocodazole (Fig. 2-10C).  At t-0, Figure 2-10A shows there was 92.8% (+/- 3.4%, n = 50 
cells) colocalization of M and N, whereas at t-120 (Fig. 2-10B) most of the M had 
separated from the nucleocapsids as indicated by only 31.3% (+/- 8.2%, n = 50 cells) 
colocalization (Fig. 2-10B).  As previously reported by others (42), we also observed that 
rVSV-M-Lumio-Green established a productive infection without an organized 
microtubule network (Fig. 2-10C).  These results suggest that the physical separation of 
M-Lumio-Green from N protein observed by confocal microscopy represents the end 
result of an uncoating event which can lead to a productive infection, and that this 
uncoating event does not require an intact microtubule network. 
 
 
Discussion 
 
Recently visualization within live cells of Ebola VP40 (164) and HIV-1 integrase 
(5) has been reported using a fluorescent LumioTM technology developed within the last 
decade (2, 70).  Fluorescently tagged viral proteins using GFP to study entry dynamics 
and intracellular trafficking of HIV-1 (25, 152) and VSV (41, 42, 202) have also been 
used.  Although the G (41, 202) and P (42) proteins of VSV have been fluorescently  
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Figure 2-8.  Distribution of M-Lumio-Green in the presence of cytochalasin D. 
(Top panels) Representative images of fixed cells from t-60 of a synchronized fusion 
assay showing distribution of M-Lumio-Green, actin, and Nup62.  (Bottom panels) The 
same experiment and labeling as above except the cells were treated with cytochalasin D 
for 30 minutes before NH4Cl washout and cytochalasin D remained in the post washout 
media until cells were fixed 60 minutes later.  Arrows indicate nuclear envelope 
localization.  For all the images in this figure signal levels were enhanced using Canvas 
11 software to maximize the Lumio-Green signal after conversion to grayscale (A and B). 
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Figure 2-9.  Distribution of M-Lumio-Green in the presence of nocodazole. 
(Top panels) Representative images of fixed cells from t-60 of a synchronized fusion 
assay showing M-Lumio-Green, tubulin, and Nup62.  (Bottom panels) The same 
experiment and labeling as in the top panels except the cells were treated with nocodazole 
to depolymerize microtubules for 30 minutes before NH4Cl washout and cells were 
maintained in the presence of nocodazole until the cells were fixed at t-60.  Arrows 
indicate nuclear envelope localization.  For all the images in this figure signal levels were 
enhanced using Canvas 11 software to maximize the Lumio-Green signal after 
conversion to grayscale (A and B). 
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Figure 2-10.  Release of RNPs from M-Lumio endosomes and productive infection  
in the presence of nocodazole. 
Representative confocal images of cells inoculated with  
rVSV-M Lumio-Green (MOI 100) at t-0 (A) and t-120 (B and C), post NH4Cl  
washout, in the presence of cycloheximide and nocodazole (B) or just  
nocodazole (C), and stained for VSV N protein using N mAb conjugated to rhodamine.   
Colocalization of M and N was measured post fusion using the colocalization function in  
the LSM software version 3.2 and the percent colocalization of (M/N) is indicated for t-0  
(A) and t-120 (B).  
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tagged with GFP and studied, there have been no reports of fluorescently tagged M 
proteins within virions for the study of M’s fate after entry.  Here we report the 
development and characterization of rVSVs with fluorescently tagged M using GFP 
(rVSV-M-MFC) and LumioTM technology (rVSV-M-Lumio-Green).  rVSV-M-Lumio-
Green was the best of these two virions for entry studies where the fate of the M-Lumio-
Green protein could be followed without the need for antibodies and due to epitope 
restriction in previous studies could be seen for the first time at the nuclear envelope after 
entry (Fig. 2-6, bottom panel arrows).   
 
Previously, the M protein was fused to GFP and GST to study the 
nucleocytoplasmic transport, nuclear localization signal (69, 168, 204), and 
mitochondrial localization (123) of the M protein.  Except for the mitochondrial 
localization study (123), the majority of these fusions were at the N-terminus.  However, 
the effect of these M fusions on assembly of VSV virions was not examined.  In these 
studies the N and C-terminal fusions did not affect the M activity studied (69, 123, 168).  
However, the N-terminus of the M protein is important in the assembly of virions as this 
portion of the protein contains the membrane association region (30, 31, 120, 217) and 
the PY motif (80, 91).  In particular, membrane associated M has been shown to be 
important for binding RNPs to the membrane and is thought to act as a bridge between 
the membrane and RNP of virions (30, 31).  In addition, the PY motif at the N-terminus 
of M is important for budding activity and therefore budding of virions from the host cell 
(80, 91).  With this in mind we fused GFP to the C-terminus (Fig. 2-1A, MFC).  
Surprisingly, we found that large C-terminal extensions, such as GST and GFP, can affect 
M protein’s budding activity (Fig. 2-2B lanes 3 and 4) although there was no apparent 
effect on M distribution to the plasma membrane (Fig. 2-2A).  To our knowledge, this is 
the first example of a fusion at the C-terminus of M affecting M’s budding activity, 
whereas only N-terminal mutations have been previously shown to effect this activity 
(91).  Attempts to recover virions expressing MFC proteins (-II, -III, -IV, and M-GST as 
well) as the sole M contributing to assembly were unsuccessful and we attributed this 
failure to the inability of these proteins cause budding.  We were able to recover rVSV 
expressing both Mwt and MFCs and when the location of MFC within rVSV-M-MFC 
virions was examined in Figure 2-2D, it was found to be associated mainly with the RNP 
pellet (lane 9) versus the solubilized membrane fraction (lanes 10).  This result showed 
that MFC, despite the large C-terminal extension, associated with RNPs and was almost 
excluded from the membrane of virions, which was surprising since MFC was clearly at 
the plasma membrane of rVSV-M-MFC infected cells (Fig. 2-2E, arrows).  Although the 
majority of MFC within the virions was found with RNPs, it was only present at 5% of 
the total M protein population.  Assuming that each virus particle has approximately 
1,800 molecules of M protein (199), rVSV-M-MFC virions would average around 90 
molecules of MFC.  Based on a previous report, this amount of GFP within the virions 
may not be enough to visualize by microscopy since it was shown that 120 molecules of 
eGFP were sufficient for detection of individual rotavirus particles (28) whereas PeGFP 
virions (VSV-PeGFP) containing almost half of the 450 approximate copies of P per 
nucleocapsid could be visualized under high magnification, live-cell microscopy (42).  
The discrepancy between rVSV-M-MFC (~90 MFC copies) and VSV PeGFP (~225 
PeGFP copies) virions could also be due to the inability of the GFP fused to M to 
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undergo the proper conformational change to fluoresce.  Also, there could be one 
population of virions with high MFC content and others with hardly any MFC which 
could lead to our inability to correlate plaque forming units (PFU) and percent MFC with 
the expected fluorescence at laser excitation of 488nm, especially when one considers the 
particle to PFU ratio of 1 to 200 (145) or 1 to 1,000 for VSV (unpublished lab data 
comparing genomic RNA to PFU).   
 
We were able to recover rVSV with fluorescent M using LumioTM technology 
which utilizes a tetracysteine (-CCRECC-) motif that binds to membrane permeable 
Lumio-fluorophores that fluoresce when bound to this motif (2, 70).  We fused the 
LumioTM tag to the N and C terminus of M and observed that the distribution of Lumio-
M and M-Lumio was similar to Mwt and unlike the larger C-terminal extension of MFC, 
M-Lumio with its smaller extension was able to retain a budding activity comparable to 
Mwt (Fig. 2-3B lane 6), whereas Lumio-M was reduced in its budding activity (Fig. 2-3B 
lane 4).  Lumio-M or M-Lumio was able to support VSV assembly as the sole M protein 
expressed from rVSV-M-Lumio genomes.  Characterization of the growth kinetics of the 
recombinants showed that rVSV-M-Lumio was the best virus to use of the two tagged 
versions (Fig. 2-3C) and the protein to PFU ratio (Fig. 2-4B, left-hand gel) showed that 
this construct was able to grow and incorporate other viral proteins to similar levels as 
wild-type virus.  The N-terminal tag results supported our original apprehension of fusing 
a tag at that terminus.  Next, we showed that M-Lumio could be labeled with LumioTM 
Green (M-Lumio-Green) during infection and unlike the entry study involving the 
labeling of HIV-1 integrase protein within virions with LumioTM reagent in vitro (5), we 
could only label rVSV-M-Lumio virions within cells.  Even though LumioTM Green is 
membrane permeable, rVSV-M-Lumio virions were not able to be labeled in vitro and we 
hypothesize that this may have to do with the compact nature of the M-Lumio within the 
virion where the LumioTM tag is not accessible or cannot flex in order to bind to the 
fluorophore. 
 
In the synchronized entry assays, the bulk of M-Lumio-Green at 20 minutes post 
warm-up was associated with perinuclear endosomes and a smaller proportion at the 
nuclear envelope.  This pattern was interesting as it was shown previously that ~15% of 
input M could be found soluble within the cytosol after entry (174) and may account for 
our observation that the bulk of input M is not in the cytosol.  In the synchronized fusion 
assays, we were able to show that M-Lumio-Green localized to the nuclear envelope after 
fusion (Fig. 2-6, bottom panels).  We believe the localization to the nuclear envelope is 
indicative of M-Lumio-Green associating with nuclear pore complexes (NPCs), as the 
localization is in the same area as Nup62 as shown by the blue staining in the merged 
image of figure 2-6.  We did not expect to see clear colocalization of the proteins since M 
associates with RaeI and Nup98 at the NPCs (53) and not directly with Nup62.  The 
nuclear envelope association was similar to that of GFP-M association with NPCs as 
shown in a study of M binding to NPCs (168).  This same study reported that M is not 
labeled by the monoclonal antibody (23H12) for M (Fig. 6, t-60, arrows, anti-M-
Rhodamine), which recognizes the motif that binds to RaeI, and can prevent its binding 
and localization to the NPCs (53, 168).  Because we did not require antibody to visualize 
M-Lumio-Green we were able to observe released M that was distributed to the nuclear 
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envelope and to our knowledge this is the first reported observation of this type of 
distribution after entry.  We propose that upon VSV entry into host cells, released M 
protein associates at the NPCs to block nucleocytoplasmic transport (84), giving the virus 
an advantage over the host cell by blocking host cell mRNA transport (84) and thus the 
innate immune response (193) before viral protein synthesis has begun.   
 
To address what the M-Lumio-Green associated perinuclear bodies were, we 
looked at markers for the endocytic pathway that corresponded to lysosomes, late 
endosomes/lysosomes, and early/recycling endosomes.  A small proportion of M-Lumio-
Green colocalized with LAMP-1 and Mannose-6-Phosphate receptor (Fig. 2-7A and B), 
however the bulk of colocalization was with transferrin-TR (Fig. 2-7C).  At higher 
magnification, we showed the M-Lumio-Green distribution within the endosome was 
asymmetric (Fig. 2-7D, arrows).  In contrast, we observed a uniform distribution for non-
infectious internalized ΔG-rVSV-M-Lumio-Green virions suggesting the asymmetric 
distribution seen after entry of rVSV-M-Lumio-Green was G-dependent and could be the 
result of one of two conditions.  A model for an increase in G protein binding with 
endosomal membranes at low pH has previously been proposed (59) and could explain 
the rVSV-M-Lumio-Green asymmetric distribution as virions that have not fused could 
still be bound to the inner leaflet of the endosomal membrane whereas ΔG virions would 
not be able to bind in this manner resulting in the difference between the two 
distributions.  In the other condition, the increased binding affinity of G at low pH could 
result in fusion of virions to one side of the endosome and the place where fusion occurs 
could be marked by the membrane bound M population that is now on the outside of the 
endosomal membrane after RNPs are released and this could not be seen as ΔG virions 
lack the ability to fuse with the endosomal membrane.  Here we hypothesize that the viral 
envelope associated M-Lumio-Green is on the cytosolic side of the endosomal membrane 
of early endosomes, after fusion, at the site of fusion.   
 
While there is a need for microtubules to traffic vesicles within the endocytic 
pathway (74), it has been shown that VSV has the ability to fuse with early endosomes 
and release its genome prior to Rab7 dependent trafficking (54, 189).  The distribution 
observed after fusion (Figs. 2-8 and 9) and the M and N separation (Fig. 2-10B) in the 
presence of cytoskeletal inhibitors seem to support the hypothesis that fusion and release 
from early endosomes is the main entry pathway.  The change in N staining (Fig. 2-10A 
and B) at t-120 in the presence of nocodazole and cycloheximide could be the result of 
two conditions; (i) protein synthesis was not completely blocked or (ii) the uncoating of 
genomes has increased the amount of N protein that is available for staining, since the 
scanning parameters (detector and gain settings) and amount of antibody for each 
condition were kept the same.  We also observed some LAMP-1 and M-6-P-R 
colocalization with virus in Figures 2-7A and B which showed VSV can reach later 
points in the endocytic pathway such as the endosomal carrier vesicles/multivesicular 
bodies further along the pathway where it has been reported to undergo a back fusion 
event for entry (117).   
 
The ability of M-Lumio-Green to localize to the nuclear envelope without fully 
polymerized actin (Fig. 2-8, arrows bottom panel) or tubulin (Fig. 2-9, arrows bottom 
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panel) was unexpected since the localization seen in the synchronized entry assays 
occurred within 20 minutes of post warm-up (Fig. 2-5, arrows bottom panel) which 
suggested trafficking would be involved, along with the fact that M has nuclear 
localization signals (69).  We conclude that after uncoating, M-Lumio-Green distributes 
to the nuclear envelope without the full cytoskeletal network that is known to contribute 
to transport within cells (183) and therefore may get there by diffusion, but we also have 
not directly ruled out delivery of M to the nuclear envelope by vesicular trafficking.  Also 
it has been shown that RaeI binds to microtubules in mitotic spindle complexes (17, 215) 
and M may bind this protein in the cytoplasm and enter the NPCs in this manner. 
 
Here we considered delivery of M-Lumio-Green to the nuclear envelope (Fig. 2-
9, bottom panel arrows), separation of M and N (Fig. 2-10B), and productive infection 
(Fig. 2-10C) after microtubule dissociation as clear indicators that uncoating occurs at 
early endosomes along the endocytic pathway.  The distribution that we observed was 
different from the completely cytosolic and nuclear distribution of M we expected after 
uncoating (174).  This difference could be attributed to the M labeling technique, lower 
MOIs, and the confocal microscopy used for this study.  Instead of visualizing uncoating 
as M being distributed throughout the cytosol as expected, we have shown that this 
process is visualized by asymmetric association of M with endosomes possibly at sites of 
fusion and delivery of a fraction of M to the nuclear envelope.  Use of rVSV with M-
Lumio-Green and other viral proteins fused to red and yellow fluorescent proteins would 
allow for a tri-fluorescent virus to study entry in greater detail giving us further insight 
into the mechanisms of VSV uncoating. 
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Chapter 3:  Low pH Enhancement of Matrix Uncoating 
 
 
Introduction 
 
Vesicular stomatitis virus (VSV), a prototype enveloped, nonsegmented, 
negative-strand RNA virus in the family Rhabdoviridae, is composed of an 11 Kb 
genome that encodes five genes (3’-N-P-M-G-L-5’).  These genes are the nucleocapsid 
protein (N), the phosphoprotein (P), the matrix protein (M), the glycoprotein (G), and the 
large RNA dependent RNA polymerase protein (L).  The virion’s structure is composed 
of a helical nucleocapsid, containing L-P-N-RNA-M, surrounded by a membrane derived 
from an infected host cell membrane with transmembrane, trimeric G proteins protruding 
from the surface.  These bullet-shaped VSV particles are 180 nm long and 75 nm wide 
with around 400 trimeric G protein spikes on the exterior of the viral membrane and 
about 1,800 molecules of M protein between the nucleocapsid core and the viral 
membrane (199).  The RNA genome is encapsidated by N protein with around 1,200 
molecules of this protein tightly complexed to the RNA like beads along a string (199).  
The RNA-dependent RNA polymerase, consisting of the L and P proteins, is associated 
with this ribonucleoprotein complex and these proteins are present at 50 and 500 
molecules per virion, respectively (199).  This L-P-N-RNA complex makes up the 
ribonucleoprotein particle (RNP) which is coiled into a tightly packed helix of around 35 
turns inside the viral membrane.  The M protein condenses the RNP into this tightly 
packed helix, which, when condensed as described, is referred to as the skeleton (153, 
154). A population of membrane bound M anchors the skeletons to the viral membrane 
(31, 151). 
 
When VSV enters the host cell through the clathrin-mediated endocytic pathway 
(139), it uses the decreasing pH of endocytic organelles as a trigger for fusion in order to 
penetrate the cell as is the case for influenza virus (207).  To enter the cell VSV virus 
attaches to the surface and is endocytosed by coated vesicles and transported through the 
endosomal pathway to early or late endosomes.  In early endosomes, pH-dependent 
fusion of the endosomal and viral membrane occurs and subsequent virus uncoating and 
release of the genome in the form of the RNP (114, 136).  The G protein of VSV is 
directly responsible for entry steps attachment and fusion (18, 82, 134, 161, 198, 211) 
where fusion results in the release of the RNP core into the cytoplasm where VSV 
replication occurs (139).  Either directly after or concomitant with membrane fusion, M 
protein dissociates from the RNP core which results in the decondensation of the skeleton 
(153, 154) and completes uncoating (174).  After uncoating, the decondensed RNP serves 
as a template for transcription of viral mRNAs by the packaged RNA-dependent RNA 
polymerase. 
 
Most enveloped virus particles entering a cell have highly condensed genomes 
protected by proteins.  Before these particles can replicate in a host cell, after fusion and 
entry, uncoating is required and this is described as the dissociation of some proteins that 
keep the genome in a condensed or a biologically inactive state.  The interesting aspect of 
uncoating is that this process is the opposite of what occurs to package the virus for 
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release.  Here lies the dilemma; how does the same protein of a virus accomplish two 
distinct processes in the same intracellular environment.  Viral uncoating, in the case of 
VSV, is regarded as the dissociation of M from RNPs and is an essential step in entry 
(130).  Without the release of M protein transcription of viral mRNAs (productive 
infection) cannot proceed since it has been shown that M protein inhibits transcription 
(32, 44, 212).  This essential step is also shared by influenza virus, another negative-
strand RNA virus, which requires removal of its matrix protein (M1) for a productive 
infection (102, 137).  While in endosomes the M2 protein of influenza virus acts as an ion 
channel (110, 169) that allows protons across the viral envelope (81).  Acidification of 
the virus interior decreases the interaction between M1 and nucleocapsids allowing for 
their dissociation before entry of the nucleocapsids into the cytoplasm (222).  VSV lacks 
a similar proton channel, though previous studies have found that spike proteins of 
enveloped viruses such as VSV, Sindbis virus, and Semliki Forest virus and Ebola virus 
GP2 can increase membrane permeability (76, 101, 112).  Though not studied in the 
context of virus it has been suggested that the haemaglutinin (HA) protein of Influenza at 
the pH required for fusion can also cause cell permeability and proton influx when found 
on the cell membrane (182).  As with influenza virus M1, VSV M protein is found within 
the cytoplasm of the host cell in soluble form separated from nucleocapsids (174).  
However, the regulatory elements involved in the dissociation of M protein from RNPs 
are still not understood.  In vitro studies using biophysical measurements at physiological 
ionic strength (60-90mM NaCl) showed that the association of M with the RNP had the 
characteristics of a dynamic reversible equilibrium (130).  This suggested that M protein 
will dissociate from skeletons in the cytoplasm of newly infected cells, and later in 
infection the concentration of M is high enough for equilibrium to be reached with 
regards to cytoplasmic and skeleton associated M (130).  These in vitro observations 
could explain why dissociation and association of M can occur under the same ionic 
conditions, however little is known about the contribution of host factors in dissociation 
and the distribution of M protein during uncoating. 
 
To study the release of M protein during uncoating, we developed and 
characterized a recombinant VSV (rVSV, (rVSV-M-Lumio-Green)) encoding an M 
protein that could be fluorescently tagged and gave us the ability to follow the fate of 
fluorescent M during entry of virions (Chapter 2).  Here, we report that there is a transient 
loss of fluorescence intensity of rVSV-M-Lumio-Green virions at early times after the 
initiation of endocytosis in a synchronized entry assay.  In vitro, rVSV-M-Lumio-Green 
particles had strong fluorescence when excited at a wavelength of 508nm at pH 7, but 
there was a dramatic loss in fluorescence when the pH was lowered.  Based on the pH-
dependent fluorescence properties of LumioTM Green, this observation suggested that the 
interior of the virion was becoming acidified.  We found that the effect of pH on the M-
Lumio-Green fluorescence within intact virus was G-dependent and further biochemical 
analysis indicated that low pH resulted in an enhancement of M dissociation from 
partially permeabilized but intact virions.  We propose a model for the initial uncoating 
events of VSV based on our observations and past viral spike protein membrane 
disruption studies (76, 101, 112, 182). 
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Materials and Methods 
 
 
Viruses.  rVSV-wt was used in biochemical analysis of 35S-Methionine labeled 
virions.  rVSV-M-Lumio-Green (Chapter 2) was used in live-cell synchronized entry 
assays (in BHK-21 cells at MOI 50) and in the fluorometric assays.  ΔG-rVSV-M-
Lumio-Green pseudotyped with either G or G-stem (GS) with a N-terminal 
haemaglutinin (HA) tag (GSHA) complemented ΔG-rVSV-M-Lumio-Green were also 
used in the fluorometric assays.  ΔG-rVSV-M-Lumio-Green were complemented with G 
or GSHA by methods used in previous studies (93) with some modifications.  Briefly, 
BHK cells at ~80% confluency were transfected with 2 µg of pC-G or -GSHA plasmid and 
infected with G-complemented ΔG-rVSV-M-Lumio-Green at MOI 10 at 18 hours post 
transfection.  The Lumio-tagged viruses were labeled as done previously (Chapter 2) 
using 200nM LumioTM Green in Opti-MEM I at 4 hours post infection.  Eighteen hpi the 
viral supernatants were collected and ultracentrifuged over a 20% sucrose cushion at 
38,000 rpm in an SW41 swinging bucket rotor (Beckman) to pellet the virions.  The 
supernatant and sucrose cushion were then removed by aspiration and the viral pellet was 
resuspended on ice in 10% sucrose TN solution (10 mM Tris-HCl [pH 8.0], 150 mM 
NaCl).  Residual unbound LumioTM Green reagent was removed from the virus 
preparation by passing 100 µl aliquots through Sephadex G-50 (Fine) columns (Roche) 
by centrifugation according to the manufacturer’s instructions.  The void volume was 
then analyzed for the fluorescence intensity using a fluorometer (Perkin Elmer LS 50 B) 
and protein composition was analyzed by Coomassie stained SDS-PAGE in which 
equivalent fluorescence was loaded.  Viral preparations were used immediately resulted 
in disruption of the viral envelopes.  
 
 
Live-cell synchronized entry assay.  To examine entry of labeled virus into live 
cells, ΔG or rVSV-M-Lumio-Green (MOI 50) together with 50 µg of transferrin-TR were 
added to BHK-21 cells in 35 mm glass bottomed culture dishes (MatTek Corporation) at 
90% confluency after cells had been washed twice with 2ml of ice-cold Opti-MEM I.  
After the ice-cold wash, the plates were placed at 4oC for 10 minutes and (as done 
previously Chapter 2). The virus and transferrin-TR were adsorbed for 90 minutes in 100 
µl ice-cold Opti-MEM I with rocking every 15 minutes at 4oC.  The cells were covered to 
prevent light photobleaching.  Five plates of cells were used per experiment, each 
corresponding to a 5 minute time point post entry.  After the 90 minute adsorption, 37oC 
media was added to initiate entry.  The binding of rVSV-M-Lumio-Green and transferrin-
TR at the non-entry time point (t-0) was observed by laser scanning confocal microscopy 
(Zeiss LSM 510) following addition of 2 ml of ice-cold Opti-MEM I.  Separate plates 
were used to examine entry after addition of 37oC media 5, 10, 15, and 20 minutes (t-5, t-
10, t-15, t-20) by confocal microscopy.  Pixel intensity of rVSV-M-Lumio-Green 
fluorescence was analyzed using the Profile function of LSM software (version 
3.2).within transferrin-TR containing endosomes and then plotted as mean pixel intensity 
as a function of time.  GraphPad software was used to calculate the P values by the two-
tailed t-test for the statistical analysis of the mean pixel intensity. 
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Fluorometric assay.  To measure the fluorescence intensity of rVSV-M-Lumio-
Green virions in vitro, we placed 1 µg of the virus in HMN (HEPES 10mM, MES 10mM, 
NaCl 150mM, pH 7) buffer and measured the fluorescence signal over 10 seconds at 1 
second intervals for each measurement with a Perkin Elmer LS 50B.  To determine the 
effect of pH on fluorescence intensity of, we recorded the fluorescence signal at pH 7 and 
added 1M NaOH to raise the pH to 7.5 and then 8 taking readings at each point.  We then 
dropped the pH by adding 1M HCl to reach a pH of 6.5, 6, 5.5, or 5 with fluorescence 
signal recorded for each pH.  These readings were then quantified as a percentage of 
fluorescence intensity loss from the pH 7 signal. 
 
To determine if G was important for the decrease in fluorescence intensity signal 
of rVSV-M-Lumio-Green virions, we applied the same protocol for the pH-dependent 
fluorescence intensity measurements of ΔG-rVSV-M-Lumio-Green and GSHA 
complemented ΔG-rVSV-M-Lumio-Green virions.  These virions were normalized to the 
same fluorescence signal for each experiment (since these are not infectious) and were 
based on the ΔG-rVSV-M-Lumio-Green signal since this virus produces the lowest 
amount of virus.  Virions were then analyzed by SDS-PAGE based on their fluorescence 
signal.  To determine if the viral envelope was a barrier to the pH effect on M-Lumio-
Green signal, virions were solubilized HMN buffered to pH 5.5 with 0.1% Triton X-100 
(w/v) after the initial readings at pH 5.5, and the percent fluorescence loss was measured 
from pH 7 readings. 
 
 
35S-methionine labeling of rVSV-wt.  BHK-21 cells were infected with rVSV-
wt at MOI 5.  At 4 hours post infection the cells were starved of methionine for 30 
minutes and then 35S-methionine in methionine-free DMEM (50µCi/ml) was added to the 
cells.  Fourteen hours post infection the virus was isolated from the supernatant by 
ultracentrifugation (27K rpm, Beckman SW-28) over a 20% sucrose TN cushion for 1.5 
hours.  The amount of protein in the viral preparation was determined using a BCA 
protein assay (Pierce) following the manufacturer’s instructions.     
 
 
Lysolecithin treatment of rVSV-wt.  To test the effect of on internal VSV 
proteins, we applied a method of gently “poking holes” in the viral envelope using the 
mild detergent lysolecithin that has been used to permeabilize cells in other studies (6, 
124).  To determine the appropriate concentration to use, we treated 1 µg of 35S-
methionine labeled rVSV-wt with varying concentrations of lysolecithin ranging from 0, 
3.9, 7.8, 15.6, 31.2, and 62.4 µg/ml at pH 5.5 for 10 minutes on ice.  The suspension was 
ultracentrifuged for 35 minutes (45K rpm, Sorvall AH-650) over a 20% sucrose TN (10 
mM Tris-HCl pH 8, NaCl 150mM) cushion to separate the proteins in the supernatant 
from the virus that pelleted to the bottom of the tube.  The supernatant was TCA 
precipitated, resuspended in reducing sample buffer, and loaded onto SDS-
polyacrylamide gels and compared to the whole pellet by fluorography.  
 
To compare protein in the supernatant of virions treated with lysolecithin at pH 7 
and pH 5.5, we treated 1 µg of 35S-methionine labeled rVSV-wt with lysolecithin at a 
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concentration of 3.9 µg/ml in HMN buffer at pH 7 or pH 5.5.  We prepared the mixes as 
stated above and quantitated the amount of 35S-methionine labeled M protein in the 
supernatant to the N protein in the pellet by phosphorimaging. 
 
 
TEM of rVSV-wt treated with lysolecithin.  To confirm virions were not 
disrupted by lysolecithin treatment 1 µg of rVSV-wt was treated with lysolecithin (3.9 
μg/ml) in HMN buffer at pH 7 or pH 5.5 and ultracentrifuged over a 20% sucrose 
cushion.  The pellets were resuspended in 10% sucrose and placed on ice.  To decrease 
the sucrose concentration, the virus preparations were then diluted 1:10 in dH2O and 
prepared for transmission electron microscopy (TEM) by adsorbing virus to a grid using 
the drop-to-drop method and negative staining with 2% phosphotungstic acid (PTA, pH 
5.9). 
 
 
Results 
 
 
Loss of fluorescence intensity over time during rVSV entry.  To follow the 
entry of ΔG (bald) or rVSV-M-Lumio-Green (G containing) virions into live cells, we 
adsorbed virus (MOI 50) onto cells at 4oC to synchronize their entry as described in 
Chapter 2 for figure 2-5.  We used transferrin conjugated to Texas Red (transferrin-TR) 
as an endosomal marker during endocytosis of the virions and the cells were observed 
using confocal microscopy every 5 minutes over a 20 minute span, post addition of media 
at 37oC.  Single images from parallel sets of plates were collected at identical detector 
and gain settings for each time point, and in which the threshold value was set to ensure 
no pixel saturation occurred.  By keeping the settings the same, and below threshold, we 
quantified the average fluorescence intensity from multiple cells between time points.  
We observed that the fluorescence intensity of rVSV-M-Lumio-Green virions decreased 
over the time course of entry (Fig. 3-1A, left-hand graph).  These data (n=50 per time 
point in triplicate) were compiled using the Profile function of the LSM 510 software 
(Zeiss version 3.2), which measures peak intensity and size of fluorescent signals for 
each scan.  The size of the particles within endosomes from which the fluorescent 
intensity measurements were collected were no larger than 180nm, which is similar to the 
average length of a VSV virion (VSV’s size is ~180nm x 70nm).  Only M-Lumio-Green 
signals that colocalized with transferrin-TR were used for quantification which ensured 
the fluorescence intensity measured was within an endosome.  We observed the largest 
reduction in fluorescence intensity of rVSV-M-Lumio-Green particles at 15 minutes post 
addition of warm media, where the mean fluorescence intensity was 27% below that of t-
0.  This difference was statistically significant with a P value less than 0.0001 using a 
paired t-test for the mean intensity of particles (Fig. 3-1A, right-hand graph).  Also, when 
we compared the mean fluorescence intensity of ΔG and rVSV-M-Lumio-Green particles 
at t-15 (Fig. 3-1B) the difference was found to be 27.3% which was also statistically 
significant (p < 0.0001). 
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Figure 3-1.  ΔG and rVSV-M-Lumio-Green fluorescence intensity during entry. 
(A) From synchronized entry assay images in Chapter 2 (Fig. 2-5).   rVSV-M-Lumio-
Green virions and transferrin-TR were bound to BHK-21 cells in cold media for 90 
minutes, then the cells were washed and warm media was added to allow entry to occur.  
The fluorescence intensity of M-Lumio-Green particles, with transferrin-TR positive 
endosomes that measured ~180nm using the Zeiss LSM 50 profile software was read for 
50 particles per time point in triplicate every 5 minutes for 20 minutes (left-hand graph).  
The difference in average fluorescence intensity at 0 minutes and 15 minutes post warm 
media addition was significant.  (*, right-hand graph) p <  0.0001 using a paired t-test.  
(B) Comparison of the average fluorescence intensity of bald ΔG and rVSV-M-Lumio-
Green virions 15 minutes post warm media addition.  (*) p <  0.0001 using a paired t-test.
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Loss of fluorescence intensity of rVSV-M-Lumio-Green in the presence of 
low pH.  In the live-cell entry assay we observed a difference in mean fluorescence 
intensity of particles when bound to the cell surface at t-0 and at t-15 where most of the 
endocytosed virus would be in endosomes at the appropriate pH for fusion of the viral 
envelope and endosomal membrane (51, 58, 172) (Fig. 3-1A).  This observation was 
interesting when one considers that the apparent pKa of LumioTM Green for the 
tetracysteine motif is 5.4 (70).  We reasoned that acid pH could be responsible for the 
decrease in fluorescence intensity during entry since VSV enters the cell through the 
clathrin-mediated endosomal pathway where the lumenal pH of endosomes drops as they 
move from early to late endosomes.  To assess whether pH had an effect on the 
fluorescence of rVSV-M-Lumio-Green virions, we mimicked the drop in pH along the 
endosomal pathway by addition of HCl to a HMN (HEPES 10mM, MES 10mM, NaCl 
120mM) buffer and measured (in triplicate; standard deviations shown) the effect on 
rVSV-M-Lumio-Green fluorescence in vitro using a fluorometer.  When excited at a 
wavelength of 508nm in HMN buffer at pH 7, 1 µg of rVSV-M-Lumio-Green virions 
gave an average fluorescence reading of 34.5 (+/- 4.7) at 528nm, when excited at a 
wavelength of 508nm.  The fluorescence was similar at a pH of 7.5 and 8.0; however, we 
found that below pH 7 the fluorescence of rVSV-M-Lumio-Green progressively 
decreased as the buffer became more acidic (Fig. 3-2A).  These data confirmed that loss 
of LumioTM Green fluorescence intensity was pH-dependent.  Interestingly, at a pH of 6, 
the pH at which G-mediated fusion occurs, we observed a similar loss of fluorescence 
intensity in vitro as was seen at t-15 in cells (29% versus 27%, respectively).  We also 
observed that the curve for fluorescence intensity loss was similar to pH curves seen for 
VSV G protein-dependent fusion (51, 172).  This similarity suggested that G somehow 
contributes to the loss in fluorescence, which we interpret as exposure of M-Lumio-
Green to acidic pH within the intact virions.  
 
 
Fluorescence intensity loss of rVSV-M-Lumio-Green is G protein dependent.  
To determine if G was involved in the fluorescence intensity loss, we compared the 
responses of rVSV-M-Lumio-Green and ΔG-rVSV-M-Lumio-Green virions to low pH.  
To determine if there was a difference in the incorporation of LumioTM Green into ΔG 
virus compared to virus containing G protein we evaluated the protein to fluorescence 
ratio by Coomassie stained SDS-PAGE gels.  We observed that there was a similar 
amount of VSV proteins when normalized by fluorescence signal (Fig. 3-2B).  We then 
tested whether ΔG-rVSV-M-Lumio-Green virions would lose fluorescence in a manner 
like rVSV-M-Lumio-Green when exposed to low pH.  We measured the initial 
fluorescence of virions in HMN buffer at pH 7 and added HCl to bring the pH to 5.5 (in 
triplicate) and measured fluorescence intensity again.  The fluorescence signal of the G 
containing virus was reduced 57% while bald ΔG  virus lost only 8% (Fig. 3-2C, left-
hand bars).  To determine if removal the envelope of the ΔG-rVSV-M-Lumio-Green 
virions could result in the loss in fluorescence, we added detergent to the virion preps 
(both G containing and bald) to solubilize the envelopes and found that there was a loss 
in fluorescence intensity similar to rVSV-M-Lumio-Green virions (Fig. 3-2C, right-hand 
bars). 
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Figure 3-2.  pH- and G-dependence of fluorescence intensity loss. 
(A) Percentage of fluorescence intensity loss over a pH range from 8 to 5.5 when 
compared to fluorescence at pH 7.  rVSV-M-Lumio-Green virions were suspended in 
HMN buffered to the indicated pH and the fluorescence was read by a fluorometer in 
triplicate.  Standard deviations are shown.  (B) Representative Coomassie stained SDS-
PAGE of rVSV-M-Lumio-Green and ΔG-rVSV-M-Lumio-Green virions.  The amount of 
virus loaded was based on the fluorescence signal and 35 fluorescence units were 
examined.  (C) Fluorescence intensity loss for rVSV-M-Lumio-Green and ΔG-rVSV-M-
Lumio-Green virions at pH 5.5 plus or minus detergent when compared to fluorescence at 
pH 7.  Samples were measured in triplicate and standard deviations are shown. 
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 It was previously reported that VSV released from cells expressing G on their 
surface could incorporate a truncated version of G made up of 71 amino acids that 
contained the transmembrane domain and cytoplasmic tail (29).  It was also shown that 
ΔG-rVSV could incorporate a version of this protein that has the full cytoplasmic tail of 
G, the transmembrane domain, and the 42 membrane-proximal amino acids on the 
exterior of the envelope which was named G-stem (GS) (176).  Considering this protein 
can be found in virions that express the full-length G protein (29), we wanted to assess 
whether or not GS could be involved in fluorescence intensity loss observed at low pH 
for rVSV-M-Lumio-Green virions.  Virus containing GS and M-Lumio-Green was 
produced by complementing ΔG-rVSV-M-Lumio-Green virions with GSHA (N-terminal 
haemaglutinin (HA) tag on GS; (94)).  We also generated virus complemented with wild-
type G (wt-G) to ensure similar virus preparations were compared.  The amount of GSHA 
incorporated into the complemented virus was similar to that found in virus pseudo-typed 
with wt-G as determined by immunoblot analysis using a monoclonal antibody to the 
cytoplasmic tail of G on an immunoblot (Fig. 3-3A).  Equivalent amounts of the two 
viruses based on fluorescent signal were treated at pH 5.5 and the reduction in 
fluorescence intensity from pH 7 was compared.  We observed a larger loss of 
fluorescence signal with the GSHA complemented virions versus ΔG-rVSV-M-Lumio-
Green virions; however the reduction was not as much as the virus with the full-length G 
protein (Fig. 3-3B). 
 
 
Low pH enhances release of M protein from VSV virions.  To determine if the 
loss in fluorescence observed when rVSV-M-Lumio-Green is exposed to low pH 
represents a biologically relevant acidification of the virion interior we asked whether 
internal viral proteins were affected when virus was suspended in low pH buffer.  We 
hypothesized that low pH may be important for virus uncoating as had been shown for 
influenza virus (222), therefore we gently “poked holes” in the viral envelope using 
lysolecithin (6, 124), in the presence of low pH to allow any pH affected proteins on the 
inside of the virion to be released into the supernatant.  To establish the conditions 
necessary to permeabilize virions without solubilizing the viral envelope, we labeled 
rVSV-wt virions with 35S-methionine and treated them at pH 5.5 in HMN buffer with 
different concentrations of lysolecithin and pelleted the mixture over a sucrose cushion 
where the released proteins would be in the supernatant and retained proteins in the viral 
pellet (Fig 3-4A).  With the loss of G protein in lower lysolecithin concentration 
treatment we established appropriate conditions for our analysis (Fig. 3-4A).  We also 
confirmed that the lysolecithin (3.9 µg/ml) treated virions at pH 7 or pH 5.5 were intact 
by negative stain transmission electron microscopy (TEM) (Fig 3-4B), indicating that we 
were observing the release of M from the virions rather than from disrupted RNPs.  When 
virions were treated with either 3.9 or 7.8 µg/ml lysolecithin at pH 5.5 some of the M 
protein was released and remained in the supernatant.   
 
To determine if there was a difference in the amount of M released into the 
supernatant at pH 7 versus pH 5.5, we treated 1 µg of virions with or without lysolecithin 
in HMN buffer at pH 7 or pH 5.5 for 10 minutes on ice and then ultracentrifuged the 
mixtures over a sucrose cushion to separate any released protein in the supernatant from  
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Figure 3-3.  Effect of GSHA on fluorescence intensity loss. 
(A) Immunoblot using monoclonal antibody to the cytoplasmic tail of the G protein to 
assess relative levels of G and GSHA incorporation into ΔG-rVSV-M-Lumio-Green 
virions.  The amount of virus loaded for each sample was based on the fluorescence 
signal and 35 units of fluorescence were examined.  (B) Fluorescence intensity loss for G 
and GSHA complemented ΔG-rVSV-M-Lumio-Green virions at pH 5.5 when compared to 
pH 7 fluorometer readings in triplicate and standard deviations are shown
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Figure 3-4.  Lysolecithin treatment of rVSV-wt. 
(A) Fluorograph of 35S-methionine labeled rVSV-wt treated with different lysolecithin 
concentrations in HMN buffer at pH 5.5.  The mixtures were ultracentrifuged over a 
sucrose cushion and the pellet and TCA precipitated supernatant were run on an SDS-
PAGE gel.  (B) Transmission electron microscopy of rVSV-wt in HMN buffer at pH 7 or 
pH 5.5 treated with lysolecithin at a concentration of 3.9 µg/ml.  100,000x Bar equals 
150nm. 
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protein retained in the virions.  There was no protein release when virus was in the 
absence of lysolecithin at either pH; however, we observed a difference in the amount of 
M released from lysolecithin permeabilized virus in HMN buffer at pH 7 and pH 5.5 
(Fig. 3-5A).  Quantification of the amount of M released as determined by the ratio of 
M/N for virions treated with lysolecithin was 15% (+/- 1 SD) at pH 7 and 28% (+/- 2 SD) 
at pH 5.5 (Fig. 3-5B).  Therefore, low pH enhanced the release of M protein from virions, 
but was not absolutely required. 
 
 
Discussion 
 
Directly after or concomitant with viral membrane fusion to the endosomal 
membrane, VSV M protein dissociates from the RNP core which results in the 
decondensation of the skeleton (153, 154) and the RNP is released into the host 
cytoplasm thereby completing uncoating (174).  After uncoating, the decondensed RNP 
serves as a template for transcription of viral mRNAs by the packaged RNA-dependent 
RNA polymerase.  This uncoating process is the opposite of what occurs when virus is 
assembled from infected cells.  The exact mechanisms by which VSV can accomplish the 
two distinct events for the same protein are not fully understood.  Uncoating of another 
enveloped negative-strand RNA virus, influenza virus, requires removal of its matrix 
protein (M1) for a productive infection (102, 137).  The mechanism for uncoating of 
influenza virus has been shown to be influenced by pH with the M2 protein of influenza 
virus acting as an ion channel (110, 169) that allows protons across the viral envelope 
(81).  Acidification of the virion interior decreases the interaction between M1 and 
nucleocapsids allowing for their dissociation before entry of the nucleocapsids into the 
cytoplasm (222).  To understand the uncoating mechanism of VSV, we developed and 
characterized the virus rVSV-M-Lumio-Green which gave us the ability to follow 
fluorescent M release and distribution during entry of virions in live-cell studies (Chapter 
2).  rVSV-M-Lumio-Green virions were constructed with an M protein that has a C-
terminal fusion to a tetracysteine (-CCRECC-) LumioTM tag.  This allowed the 
fluorescent labeling of M with the biarsenic fluorescein reagent LumioTM Green (2, 64, 
70). 
 
During live-cell synchronized entry assays we observed a loss in fluorescence 
intensity of rVSV-M-Lumio-Green virions during endocytosis of virus after the addition 
of warm media.  The reduction in fluorescence signal peaked at 15 minutes post warm 
media addition (Fig 3-1) and then steadily increased thereafter.  When we considered the 
pKa of the interaction between the fluorophore and the tetracysteine motif  (70), the data 
suggested that the acidic environment of endosomes at t-15, where most of the 
endosomes would be near the appropriate pH for fusion of the viral envelope and 
endosomal membrane (51, 58, 172), had an effect on the fluorescence of rVSV-M-
Lumio-Green (Fig. 3-1B).  Indeed, we observed an effect on fluorescence intensity when 
the pH was reduced from 7.0 to 5.5.  In fact, the percentage of fluorescence loss seen 
within cells at t-15 (Fig. 3-1A, right-hand graph) was similar to the loss at pH 6 in vitro 
(Fig. 3-2A).  By 15 minutes the virus has likely reached an endocytic compartment with a  
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Figure 3-5.  Lysolecithin treatment of rVSV-wt at pH 7 and pH 5.5. 
(A) Representative fluorographs of 35S-methionine labeled rVSV-wt treated at a 
concentration of 0 or 3.9 µg/ml lysolecithin concentrations in HMN buffer at pH 7 or pH 
5.5.  (B) Quantification of M protein release as determined by the percentage of M in the 
supernatant when compared to the amount of N found in the pellet.  Data are the mean 
and standard deviation for the experiment performed in triplicate.
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pH close to 6.0 (75).  We also observed that the curve for fluorescence intensity loss was 
similar to pH curves for VSV G protein pH-dependent fusion (51, 172) further suggesting 
a correlation between pH-dependent conformation changes in G and the effect resulting 
in changes in M-Lumio-Green fluorescence.  We then compared the fluorescence 
intensity loss of ΔG-rVSV-M-Lumio-Green and virions complemented with G (Fig. 3-
2C) and GSHA (Fig. 3-3) in the presence of low pH and found that the full-length G 
protein was needed for the maximal effect of pH on fluorescence in vitro. 
 
When we considered the pKa of LumioTM Green when bound to the tetracysteine 
motif and compared the loss of fluorescence between G, and ΔG virions either treated or 
not treated with detergent (Fig. 3-2B), we concluded that G in the presence of acidic pH 
was responsible for acidification of the interior of rVSV-M-Lumio-Green virions.  This 
was an interesting result since influenza virus uses the M2 ion channel protein for 
acidification of the virion interior (110, 169) and our results suggested that VSV uses a 
different method to accomplish a similar feat with its G protein.  Previous studies have 
found spike proteins of several different enveloped viruses including VSV, Sindbis Virus 
(SIN), Semliki Forest virus (SFV), influenza HA, and Ebola virus GP2 when exposed to 
acidic pH, can increase membrane permeability when cells expressing these proteins on 
the cell surface are exposed to low pH (76, 101, 112, 182).  The SFV spike protein’s 
involvement in membrane disruption at low pH was extensively studied with cell 
permeabilization assays, whole-cell patch-clamp recordings, and dual voltage-clamp 
intracellular current flow monitoring (112, 113, 115) and was predicted to be due to pore 
formation by the E1-E2-E3 protein trimers that make up the SFV spike (114).  However, 
the mechanism of how G protein may permeabilize the VSV envelope has yet to be 
investigated.  The G protein may form a pore while under going pH-dependent 
conformational changes (161, 177, 178) or rearrangement of G protein trimers to the 
virion poles (22) may cause enough disruption of the envelope to allow protons to the 
interior of the virion. 
 
The influenza virus M1 protein is affected by low pH  within the virion which has 
been shown to decrease the interaction between M1 and nucleocapsids resulting in their 
dissociation before entry of the nucleocapsids into the cytoplasm (222).  It has also been 
proposed that the capsid protein of SFV is affected by pH in a similar manner that would 
allow for efficient uncoating and association of its genome with ribosomes (114).  After 
our observation that pH affected the fluorescence intensity of M-Lumio-Green within 
virions in a G protein and pH-dependent manner (Fig. 3-2), we reasoned that exposure to 
low pH may affect the M proteins within VSV virions in a similar manner.  It was 
previously shown that M protein exists in a dynamic equilibrium in its association with 
nucleocapsids and that low pH did not have an effect on this equilibrium (130).  
Consistent with the results of that study, we found that skeletons treated with pH 5.5-6.0 
did not release M protein from RNPs (data not shown).  Even though these results 
suggested that pH has no effect on the association of the population of tightly bound M 
associated with RNPs, we reasoned that low pH may affect a different population of M 
inside the virion, in particular the M associated with the viral envelope that acts as a 
bridge to the nucleocapsid (31, 120, 221) versus the M associated with the nucleocapsid 
after isolation from solubilized virions (10, 100, 153).  Indeed, virions treated with 
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lysolecithin in the presence of low pH showed an enhanced release of M protein when 
compared to virions treated at neutral pH (Fig. 3-5).  It is important to note that low pH 
may not be absolutely necessary for uncoating to occur since VSV pseudotypes having 
envelope that are pH-independent and that fuse at the cell surface are still infectious (95, 
142, 159).   
 
From this study we propose that when virions are exposed to the low pH 
environment in the endosome during entry, the contact between the M that bridges the 
viral envelope and the skeletons is reduced (30) (Fig. 3-6, green circles and black rimmed 
circles respectively).  Acidification may trigger a slight structural change in M that 
reduces the interaction between M proteins and between the M and RNPs within the 
virion just before or concomitant with fusion.  This reduced contact between the M 
populations would enhance the release of the skeleton into the cytosol.  The M on the 
released skeleton could then dissociate away from the RNP into the M protein-less 
cytoplasm of newly infected cells as previously suggested (130).  In summary we report a 
low pH effect on M-Lumio-Green fluorescence within virions and a low pH enhancement 
of M released from lysolecithin treated virions that together suggests pH is one of the 
regulatory elements involved in VSV uncoating.  Although this effect is accomplished by 
a different mechanism in regards to influenza virus, it may indicate the involvement of 
low pH as a trigger for uncoating for many enveloped viruses that enter the host cell 
through the endocytic pathway. 
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Figure 3-6.  pH effect model. 
(A) Illustration of pH effect on rVSV-M-Lumio-Green fluorescence and depiction of 
what may occur to rVSV-wt when treated with lysolecithin.  (B). Model for VSV 
uncoating enhanced by endosomal pH.  Acidification of the interior of virions in early 
endosomes affects the contact between the RNP and membrane bound M proteins 
(depicted by red stars) which results in the release of skeletons from membrane bound M 
protein.  The release of skeletons could occur in either way or both ways depicted and 
then uncoating can be completed in the cytosol.  
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Chapter 4:  Examination of Mutations in the Exposed Loop of 
the VSV Matrix Protein 
 
 
Introduction 
 
Vesicular stomatitis virus (VSV) is a simple, enveloped, non-segmented negative-
strand RNA virus that has served as a model to study virus assembly. The matrix protein 
(M) of VSV plays a key role in virus assembly by condensing the RNA genome and 
influencing the budding of virions from host cells (30, 78, 91, 153).  The M protein is 
also involved in the cytopathic effects inflicted on host cells which include disruption of 
cytoskeletal organization, inhibition of host mRNA expression, translation, and 
nucleocytoplasmic transport (3, 4, 33, 53, 168). 
 
Biochemical studies have suggested that an exposed protease-sensitive loop (120-
PAVLADQGQP-129) in M may be important for assembly of virions.  Cleavage of the 
loop with the protease thermolysin resulted in a matrix protein that no longer self-
associated (65, 66).  M self-association has been implicated in condensation of the 
genome (67, 154) which is thought to result in inhibition of viral mRNA synthesis (163) 
and to be critical in assembly of bullet shaped virions (65-67, 153).  Recently M loop 
mutations at amino acids 121 to 124 were examined to assess their effect on assembly of 
virions.  The assembly effect observed was minor whereas these mutations resulted in a 
reduction of viral protein synthesis (35).  To address the involvement of the loop in virion 
assembly, before the report on residues 121 to 124, we made different mutations within 
the loop with the hypothesis that the amino acids present (aspartate residue 125 in 
particular) were important for assembly. The mutants were studied in the context of M 
protein activity, and by recovery and characterization of recombinant VSV (rVSV). 
 
Cellular distribution and budding activity of the loop mutants were comparable to 
wild-type.  However, characterization of the mutant rVSVs revealed a reduction in 
growth kinetics and viral budding activity, unlike previous rVSVs with different loop 
mutations in M (35).  Our results were consistent with the notion of that the loop may be 
involved in assembly.  In addition, 35S-methionine metabolic labeling studies revealed a 
reduction in viral protein synthesis for the rVSVs containing loop mutations from 4 to 8 
hours post infection,  as reported by others previously (35).  Real-Time RT-PCR of cells 
infected with loop mutants revealed there was more viral mRNA in mutant infected cells 
compared to wild-type infection.  A broad analysis of host responses to viral products 
that affect protein translation revealed that PKR activation, RNase L rRNA degradation, 
IFN response, apoptosis or autophagy were not involved in the reduced protein synthesis.  
We were able to show that this effect was most likely on a cap-dependent translation 
factor as translation from a Type 2 internal ribosome entry site (IRES) was not affected.  
These results suggest that the exposed protease-sensitive loop in M may be involved in 
assembly and in viral translation or that the assembly defect causes a novel host response 
to RNA virus infection. 
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Materials and Methods 
 
 
Plasmid design and construction.  Construction of the cDNAs containing the 
loop mutations in M was accomplished using pBluescript(BS) M-Lumio (Chapter 2) as a 
vector and overlapping PCR to insert the mutations.  Overlapping primers (CEM 9 and 
10, 11, 12 and 13, 14 and 15,  16 and 17, 18 and 19, 20 and 21, 22 and 23, used in that 
order for the mutations Δ Loop, 2X Loop, A Loop, D Loop, D125A, D125E, L123A, and 
L123S respectively) which encoded the mutations were used for PCR amplification with 
a 5’ forward primer (CEM 1) and a 3’ reverse primer (T3) respectively.  Another round 
of PCR amplification with the overlapping 5’ and 3’ fragments as the template and the 
two outside (CEM 1 and T-3-reverse) were used to create the desired mutations in the M-
Lumio gene.  The PCR product was gel purified, digested with AscI and EagI, gel 
purified, and ligated into pBS-SK-ΦT cut with the same enzymes. 
 
 
Generation of full-length VSV cDNAs encoding M loop mutants.  Creation of 
the full-length VSV genomes with M loop mutants was accomplished by separately 
cloning each sequence into a pΔM-PLF VSV anti-genome which has a multiple cloning 
site in the place of the M protein coding sequence (91), except GFP is not encoded in the 
plasmid.  For each construct the plasmids were digested with AscI and EagI, the ΔM 
vector and M loop mutant fragments were gel purified and ligated by two way ligation to 
create pVSV-(Loop Mutation). 
 
 
Recovery and characterization of recombinant VSV (rVSV).  Recombinant 
viruses were recovered using reverse genetics (116) with some modifications as 
described previously (91).  Single-step growth curves were performed by adsorbing virus 
to baby hamster kidney (BHK-21) cells in 35 mm plates at a multiplicity of infection 
(MOI) of 10 for 1 hour at 31oC while continually rocking.  The inoculum was removed, 
the cells were washed 4x with serum-free Dulbecco’s minimal Eagle’s medium (DMEM) 
to remove unbound virus, DMEM containing  5% fetal bovine serum (FBS) was added, 
and the cells were placed at 37oC.  Every two hours post infection (hpi) a 5% aliquot of 
media was collected, replaced with the same volume of fresh media, and then virus titers 
were determined in duplicate by plaque assay on BHK-21 cells. Growth curves were 
performed in triplicate for each virus.  Relative infectivity was assessed by Coomassie-
blue staining after SDS-PAGE analysis of 1 x 107 PFU of rVSV. 
 
 
TEM of rVSV.  To confirm the morphology of rVSV, purified virus was 
resuspended in 10% sucrose 10 mM Tris-HCl [pH 8.0], 150 mM NaCl solution and 
placed on ice.  To decrease the sucrose concentration, the virus preparations were then 
diluted 1:10 in dH2O and prepared for transmission electron microscopy (TEM) by 
adsorbing virus to a carbon-coated grid using the drop-to-drop method and negative 
staining with 2% phosphotungstic acid (PTA, pH 5.9). 
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Transient expression of M loop mutants.  BHK-21 cells at ~90% confluency on 
glass cover slips, were infected with a modified vaccinia virus (vTF7-3) encoding T7 
RNA polymerase (61) at MOI 5 for 1 hour at 31oC in SF-DMEM.  The inoculum was 
removed and the cells were transfected with 5µg of pBS-MΦT (wild-type; Indiana) or 
pBS-(Loop Mutant) using 20 µl TransfectACE in SF-DMEM (180).  Five hours post 
transfection (p.t.) the transfection mix was removed and replaced with 5% FBS DMEM 
containing antibiotics (100U/ml streptomycin and penicillin), and 18 hours p.t. the cells 
were fixed and processed for immunofluorescence or were used in a budding assay as 
described below. 
 
 
Immunofluorescence (IF) staining and confocal microscopy.  Cells either 
transiently expressing M proteins from plasmids or infected with rVSV were washed 
twice with phosphate-buffered saline (PBS) and then fixed for 15 minutes with 3% 
paraformaldehyde (PFA) in PBS at room temperature (r.t.).  The fix solution was then 
removed and the cells washed twice with PBS containing 10 mM Glycine and 0.05% 
sodium azide (PBS-Glycine), and then permeabilized with 1% Triton X-100 in PBS-
glycine at r.t. for 1 minute.  After permeabilization, the cells were washed twice with 
PBS-Glycine and then stained for; M protein using an anti-M monoclonal antibody (mAb 
23H12) conjugated to FITC or rhodamine, VSV N protein using anti-N mAb 10G4 
conjugated to rhodamine., or microtubules using anti-α tubulin mAb (# A-11126, 
Molecular Probes).  The unconjugated primary antibodies were detected with a goat anti-
mouse secondary antibody conjugated to rhodamine (Jackson Research Laboratories).  
Phalloidin conjugated to Texas Red-X (Invitrogen; Molecular Probes) was used to stain 
actin.  The distribution of the indicated proteins was examined using laser scanning 
confocal microscopy (Zeiss LSM 510).  Optical slices of 1 µm were captured using 
488nm or 543nm laser excitation. 
 
 
Budding assays.  Cells transiently expressing the indicated M protein were 
washed twice with methionine-free, SF-DMEM and then incubated in this media for 15 
minutes to deplete the intracellular methionine pools at 5 hours p.t.  After depletion, a 
media composed of 1 part 5% FBS DMEM to 9 parts methionine-free media and 
supplemented with 50 µCi of 35S-Methionine (Met) Express Protein Labeling Mix 
(Perkin-Elmer) per ml was added and 18 hours later media and cells were collected 
separately and processed for immunoprecipitation (IP). 
 
The media were centrifuged at 170 x g for 10 minutes to remove dislodged cells 
and the supernatant was placed on ice after addition of 200U of aprotonin (U.S. 
Biochemicals).  The supernatant was made to 50mM Tris-HCl, 150mM NaCl, 0.1% NP-
40, 1mM EDTA, 20mM NaN3, 0.3% SDS, and radio labeled M proteins were 
immunoprecipitated with M mAb (23H12) overnight at 40C. 
 
Cell extracts were prepared by washing the cells twice with PBS and then lysing 
with 800 µl of detergent solution (10 mM Tris-HCl [pH 7.4], 66 mM EDTA, 0.4% 
sodium deoxycholate, 1% Triton X-100, 0.05% NaN3) containing 200U/ml of aprotonin 
 65
for 5 minutes at r.t. on a rocker.  The cell extract was collected, nuclei and insoluble 
material removed by centrifugation at 10,000 x g for 5 minutes and a 200 µl aliquot of 
the cell extract was made to 0.3% SDS and immunoprecipitated with M mAb (23H12) 
overnight at 4oC.  One-quarter of the radio labeled M proteins in the cell extract were 
compared to the amount released into the supernatant by SDS polyacrylamide gel 
electrophoresis (PAGE) on a 9% polyacrylamide gel and visualized by fluorography. 
 
 
Immunoblot analysis.  To detect the proteins in BHK-21 or HeLa cells that were 
mock treated/infected, rapamycin treated, or infected with rVSV cell lysates from ~ 106 
cells were collected at different times post infection by addition 400 µl of detergent 
solution (10 mM Tris-HCl [pH 7.4], 66 mM EDTA, 0.4% sodium deoxycholate, 1% 
Triton X-100, 0.05% NaN3) containing 200U/ml of aprotonin.  The cell extracts (5%) 
were separated by SDS-PAGE on a 10% polyacrylamide gel and then transferred to a 
polyvinylidene fluoride (PVDF) microporous membrane (Immobilon-P; Millipore).  
Monoclonal antibodies to M (23H12), α tubulin (# A-11126, Molecular Probes), eIF2α (# 
9722, Cell Signaling Technologies (CST)), phosphorylated eIF2α (# 9721, CST), caspase 
3 (# 9668, CST), phosphorylated eIF4G (# 2441, CST), and LC3B (# 2775, CST) were 
used to detect each protein followed by addition of a goat anti-mouse or -rabbit antibody 
tagged with horseradish peroxidase (Jackson Research Laboratories).  Proteins were 
visualized using a chemiluminescence kit (Immobilon Western; Millipore) according to 
the manufacturer’s instructions. 
 
 
35S-methionine pulse labeling of rVSV infected cells.  BHK-21 cells were 
infected with rVSV at an MOI of 10.  At increasing times post infection the cells were 
starved of methionine for 10 minutes and then an 35S-methionine labeling mix at 
50µCi/ml was added to the cells for 10 minutes.  Cell extracts were prepared by washing 
the cells twice with PBS and then lysing with 400 µl of detergent solution (10 mM Tris-
HCl [pH 7.4], 66 mM EDTA, 0.4% sodium deoxycholate, 1% Triton X-100, 0.05% 
NaN3) containing 200U/ml of aprotonin for 5 minutes at r.t. on a rocker.  The nuclei and 
insoluble material were removed by centrifugation at 10,000 x g for 5 minutes and 5% of 
the cell extract was analyzed by SDS-PAGE fluorography and quantified by 
phosphorimaging using a STORM (Molecular Dynamics) scanner. 
 
 
rVSV budding assay.  BHK-21 cells were infected with rVSV at an MOI of 10.  
At 3 hpi, cells were starved of methionine for 10 minutes and then an 35S-methionine 
labeling mix at 50µCi/ml was added to the cells for 1 hour.  The supernatant was then 
collected and virus was isolated from the supernatant by ultracentrifugation (35 minutes, 
45K rpm, Sorvall, AH-650) over a 20% sucrose TN (10 mM Tris-HCl [pH 8.0], 150 mM 
NaCl) cushion.  Also, cell extracts were prepared by washing the cells twice with PBS 
and then lysing with 400 µl of detergent solution (10 mM Tris-HCl [pH 7.4], 66 mM 
EDTA, 0.4% sodium deoxycholate, 1% Triton X-100, 0.05% NaN3) containing 200U/ml 
of aprotonin for 5 minutes at r.t. on a rocker.  The nuclei and insoluble material were 
removed by centrifugation at 10,000 x g for 5 minutes.  The whole viral pellet and 5% of 
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the cell extract were analyzed by SDS-PAGE fluorography and quantified by 
phosphorimaging using a STORM scanner. 
 
 
Synchronized fusion co-infection assay.  To prevent the acidification of 
endosomes and synchronize fusion of virions with endosomal membranes we used the 
lysosomotropic reagent NH4Cl as described previously (174) with some modifications.  
BHK-21 cells were washed twice with PBS and then washed twice with PBS containing 
100mM NH4Cl.  rVSV (MOI 1), rVSV-D125A (MOI 10), or rVSV-wt (MOI 1) and 
rVSV-D125A (MOI 10) were adsorbed in SF-DMEM containing 100mM NH4Cl for 90 
minutes.  After adsorption the cells were washed with PBS four times to remove the 
NH4Cl and protein synthesis or virus budding was examined by 35S-methionine pulse 
labeling as described above. 
 
 
RNP exchange assay.  35S-methionine labeled M-wt or M D125A mutant protein 
was made from plasmids in a TNT T7 in vitro transcription and translation reaction (# 
L4610, Promega) in the presence of 35S-methionine labeling mix (# AG1594, GE 
Healthcare).  Five microliters of either translation reaction was added to 10, 50, or 100 µg 
of solubilized rVSV-wt or rVSV-D125A in TN (Tris-HCl (pH 8.0), 150mM NaCl) 
buffer.  The mixtures were placed on ice for 10 minutes and then the RNPs and 
supernatants were separated by ultracentrifugation (35 minutes, 45K rpm, Sorvall, AH-
650) over a 20% sucrose TN cushion.  Pellets and TCA precipitated supernatants were 
then analyzed by SDS-PAGE fluorography. 
 
 
RT-PCR analysis.  To rule out viral mRNA as the limiting factor in the reduction 
in protein synthesis during infection, real-time RT-PCR was performed on BHK-21 cells 
infected with rVSV at an MOI of 10 and at increasing times post infection cell lysates 
were collected in Trizol reagent (# 15596-018, Invitrogen) and total RNA was extracted.  
Reverse transcription was performed using a primer (MR Nest) on a known amount of 
genomes from 101 to 1013 to produce a standardized genomic curve for RT-PCR.  
Reverse transcription was also performed on total RNA extracted from cells using a poly 
dT primer for mRNA and a primer (MR Nest) that annealed to the intergenic region 
between M and G for genomes.  RT-PCR was then performed and RNA was quantified 
using SYBR Green for genomes (primers CEM 2 and MR Nest) and P mRNA (P82F and 
P-210-REV) in a DNA Engine Opticon system and software (MJ Research/BioRad). 
 
 
Luciferase assays.  HeLa cells were mock transfected, transfected with a non-
reporter plasmid, or 125 ng of a plasmid that encoded Firefly luciferase under the control 
of the IFNβ promoter (p IFNβ-Luc) that expressed luciferase.  Five hours post 
transfection of IFNβ-Luciferase plasmid cells were mock treated/infected, treated with 
125U of human IFN, or infected with rVSV-wt or rVSV-D125A at an MOI of 10.  Cell 
lysates were collected at increasing times post infection and analyzed using a luciferase 
assay system (# E1500, Promega) in a luminometer (Turner Designs, TD-20/20). 
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HeLa cells were also transfected with 2 µg of a plasmid that expressed luciferase 
from a chicken actin promoter (pCAAGs-Luc) and at 5 hours post transfection were 
mock infected or infected with rVSV-wt or rVSV-D125A at an MOI of 10 and cell 
lysates at increasing times post infection were analyzed for luciferase activity as 
described above. 
 
BSR cells (BHKs constitutively expressing T7 RNA polymerase, (179)) were 
transfected with 5 µg of a plasmid that expressed luciferase with an internal ribosome 
entry site (pEMCV/IRES-Luc) and 18 hours post transfection the cells were mock 
infected/treated, treated with cycloheximide (10 µg/ml), or infected with rVSV-wt or 
rVSV-D125A at an MOI of 10.  Mock and cycloheximide treated cell lysates were 
assessed for luciferase activity at 6 hours post treatment and luciferase activity was 
measured at increasing times post infection in infected cells as described above. 
 
 
Results 
 
 
Recovery and characterization of recombinant (r)VSV with M loop 
mutations.  To investigate the role that the amino acids within the protease-sensitive loop 
of M protein may play in virus assembly we constructed M proteins with mutations in the 
loop (Fig. 4-1A).  All of the constructs included a C-terminal Lumio tag, which we have 
shown does not affect M protein localization, budding activity, or uncoating when 
assembled into virus particles (Chapter 2).  Figure 4-2A shows an alignment of the 
putative loop regions of vesiculovirus M proteins showing that the aspartate residue 
(highlighted) is also conserved.  To determine if the loop in M had conserved sequences 
we performed a PubMed blast search of the virus protein database and Figure 4-2B shows 
the results that revealed an LXD sequence for other virus proteins.  Based on these 
alignments (Fig. 4-2), the mutations in Figure 4-1A were constructed to determine 
whether the loop (Δ Loop), size of the loop (2X Loop), or specific amino acids were 
involved in the assembly and/or uncoating of VSV. 
 
To assess the cellular distribution and assembly function of these M proteins with 
loop mutations, we transiently expressed these proteins in cells and compared them to M-
wt by immunofluorescence microscopy (IF)) and in a budding assay (Figs.4-1B and C).  
There were no discernable difference in the intracellular distributions of the M loop 
mutants as they all were located in the nucleus, were cytosolic, and localized to the 
plasma membrane as determined by reactivity with a monoclonal anti-M antibody 
conjugated to rhodamine (Fig. 4-1B).  The loop mutants also had wild-type budding 
activity (Fig. 4-1C lane 6).  Note D125A is the only mutant shown in the IF and budding 
assay but the other loop mutations retained similar wild-type activity. 
 
To determine if M loop mutants could support virus assembly we replaced the 
Mwt gene with the loop mutants in the viral genome (Fig. 4-1A).  Only the viruses with 
single amino acid mutations (D125A, L123A, and L123S) were recovered.  Although we 
did not recover the D125E mutant from plasmids, it was obtained as a “revertant” from  
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Figure 4-1.  Design and characterization of the M loop mutant proteins. 
(A) Schematic of mutations made in the protease-sensitive loop region of M and their 
location within rVSV genomes.  The residues in grey color and underlined are either 
mutated to the amino acids shown, or are added (2X Loop).  The -PP- indicates deletion 
of the loop region (Δ Loop) between the two prolines at residues 121 and 129 in the wild-
type sequence (Mwt).  All constructs contained a tetracysteine LumioTM tag.  (B) 
Transient expression of Mwt and the D125A loop mutant in BHK-21 cells stained using 
an anti-M monoclonal antibody conjugated to rhodamine and examined by LSM using a 
100X magnification objective and 543nm excitation.  Image is a 1 µm optical section 
through the middle of the cell.  (C) Budding assay showing intracellular protein 
expression (odd numbered lanes) and budding activity in mock transfected (lane 2), Mwt 
(lane 4), and D125A (lane 6) transfected cells. 
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Figure 4-2.  M loop sequence alignments. 
(A) Zoomed in view of predicted loops from matrix proteins of different Vesiculoviruses 
showing the Leucine/Isoleucine and aspartate (L/I and D respectively, highlighted) 
residue and their location in the sequences.  Alignment of matrix proteins from Gaudier 
et al. (66) using Clustal W was used to align the predicted loops. (B) Alignments and 
results of a PubMed blast search for the VSV M loop sequence, revealing an LXD 
sequence in proteins involved in some form of assembly from different viruses. 
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rVSV-D125A after 7 passages on 107 cells using an MOI of 0.001 at each passage.  As 
described below, D125A forms very small plaques and does not cause cell rounding (Fig. 
4-2A).  The D125E mutation is referred to as a revertant since it restored (data not 
shown) the cell rounding activity that was lost in the D125A mutant phenotype when 
compared to wild-type (Fig. 4-3A).  This phenotype was a significant observation since 
BHK-21 cells, which are highly susceptible to VSV cytopathic effects (CPE), did not 
round when infected with D125A.  A previous study by others showed that infection of 
MDCK cells with a rVSV M loop mutant (121-DKQQ-124, rVSV-ΦM) did not show a 
wild-type cell rounding but the mutant did in BHK cells (35).  To determine if there were 
differences in the disruption of the actin- or tubulin-based cytoskeleton within cells 
infected with wild-type or the D125A mutant, we examined infected cells by laser 
scanning confocal microscopy after staining for M and either tubulin or actin at 8 hours 
post infection (hpi).  We found that tubulin was not disrupted at this time post infection 
(Fig. 4-3B) while actin was reorganized in wild-type infected cells, but not in D125A 
infected cells (Fig. 4-3C).  The result we observed was interesting since previous studies 
using different microscopy and methods had linked the disorganization of microtubules 
as the source for virus induced cell rounding (150, 190). 
 
To determine if the growth kinetics of the M loop mutants were similar to rVSV-
wt we performed single-step growth curves for each virus.  All the mutants grew more 
slowly and had a titer of one log less than wild-type at 10hpi (Fig. 4-4A).  To assess the 
relative infectivity of the virions, proteins from 107 PFU of the rVSV-D125A and rVSV-
wt virions were separated by SDS-PAGE and Coomassie-blue stained (Fig. 4-4B lanes 1 
and 2, respectively).  The protein compositions from equivalent amounts of infectious 
virus were similar indicating the reduced infectivity for D125A found at 10 hpi in the 
one-step growth curve analysis was due to less virus being assembled and released from 
infected cells.  We then compared the morphology of purified virions by transmission 
electron microscopy using negative staining.  As seen with the relative infectivity 
analysis, the morphologies of the D125A loop mutant and rVSV-wt (Wt) were both 
bullet-shaped with helically condensed RNPs (Fig. 4-4C).  These results further 
supported the conclusion that the the reduction in growth kinetics of the loop mutants was 
due to an assembly defect. 
 
 
rVSV M loop mutants show reduced viral protein synthesis at later times 
post infection.  Previously it was shown that an rVSV M loop, rVSV-ΦM, had a defect 
in viral protein synthesis (35) without significant assembly defects.  To determine if our 
rVSV M loop mutants had similar defects in viral protein translation we infected cells at 
an MOI of 10 pulse-labeled the cells with 35S-methionine for 10 minutes at 6 hpi and 
analyzed the labeled proteins by SDS-PAGE and phosphorimaging (Fig. 4-5).  For each 
gel lane 1 shows the protein synthesis of mock infected cells.  Quantitation of the 
difference in viral protein synthesis between wild-type and the D125(E or A) loop 
mutants (Fig. 4-5A lanes 2, 3, and 4, respectively) or the L123(A or S) mutants (Fig. 4-
5B lanes 3 and 4, respectively) is represented in the graphs and shows a larger reduction 
in viral protein synthesis for the D125A mutant.  The rVSV M loop mutants showed 
similar reduced growth kinetics to each other (Fig. 4-4A), but the D125A mutant had a  
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Figure 4-3.  Cell rounding of rVSV-wt and rVSV-D125A infected cells. 
(A) BHK-21 cells were infected with wild-type (Wt) and mutant virions (D125A) at an 
MOI of 10 and phase-contrast images were taken at 24 hours post infection (hpi) showing 
reduced cell rounding in rVSV-D125A infected cells.  (B and C) Cells at 4 hpi were 
fixed, permeabilized, and stained for M (Ex. 488nm) and tubulin (B) or actin (C) (Ex. 
543nm), showing that reorganization of actin (C, Wt) correlated with cell rounding in 
rVSV-wt infected cells. 
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Figure 4-4.  Characterization of rVSV with M loop mutations. 
(A) One-step growth curve of rVSV M mutants and rVSV-wt in BHK-21 cells.  The 
results show average titers at each time point from the experiment performed in triplicate.  
The mutant rVSVs grow to one-log lower titer than Wt.  (B) Coomassie-blue stained 
SDS-PAGE of 107 PFU for rVSV-D125A (lane 1) and rVSV-wt (lane 2).  (C) 
Transmission electron micrographs of purified rVSV-D125A (D125A) and rVSV-wt 
(Wt) virions.  130,000X, bar represents 20nm. 
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Figure 4-5.  35S-methionine metabolic labeling of rVSV infected cells. 
(A) SDS-PAGE fluorography of 35S-methionine pulse-labeled BHK-21 cell lysates from 
mock infected (lane 1), rVSV-wt (lane 2), rVSV-D125E (lane 3), or rVSV-D125A (lane 
4) infected cells at 6 hours post infection (hpi).  Quantification of the percent difference 
in labeled protein (mutant N/ wt N protein) analyzed by phosphorimaging software is 
shown in the graph on the right.  (B) SDS-PAGE fluorography of 35S-methionine pulsed 
BHK-21 cell lysates from mock infected (lane 1), rVSV-wt (lane 2), rVSV-L123A (lane 
3), or rVSV-L125S (lane 4) infected cells at 6 hours post infection (hpi).  Quantification 
of the difference in protein labeled (mutant N/ wt N protein) analyzed by 
phosphorimaging software is shown in the graph on the right. 
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more pronounced reduction in viral protein synthesis at 6 hpi (Fig. 4-5).  Note all 
recovered rVSV M loop mutants were analyzed in the following sections in triplicate but 
the rVSV-D125A mutant will be the focus in each of the remaining sections. 
 
To examine the difference in protein synthesis between rVSV-wt and D125A 
infected cells in more detail, cells were pulse-labeled with 35S-methionine for 10 minutes 
at 2, 4, 6, and 8 hpi and analyzed as described for Figure 4-4.  Protein synthesis of viral 
and cellular proteins was similar for the two viruses at 2 and 4 hpi, with the characteristic 
inhibition of cellular protein synthesis seen from VSV infected cells beginning at 4 hpi.  
However, by 6 and 8 hpi there was a dramatic reduction in viral protein synthesis for the 
D125A mutant.  Lane 1 shows cellular protein synthesis of mock infected cells.  
Quantification of viral protein synthesis at 8 hpi from D125A infected cells showed an 
82% reduction compared to wild-type levels (Fig. 4-6A (lane 8) and B).  To determine if 
reduced viral protein synthesis could be observed outside of an rVSV infection, we 
transiently expressed the D125A or wild-type M proteins in cells and pulse-labeled the 
cells with 35S-methionine at 18 hours post transfection (p.t.) and analyzed cell lysates 
immunoprecipitated with an M mAb by SDS-PAGE and phosphorimaging (Fig. 4-6C, 
lanes 1 and 2, respectively).  We also analyzed protein expression using an in vitro 
transcription and translation system and compared the D125A mutant and wild-type by 
SDS-PAGE and phosphorimaging (Fig. 4-6D, lanes 1 and 2, respectively).  Expression of 
D125A without other VSV proteins or products showed no reduced protein synthesis 
(Fig. 4-6C and D, lane 1) as observed at 8 hpi (Fig. 4-6A, lane 8) when compared to wild-
type.  These data suggested that the reduced viral protein synthesis observed is not solely 
due to the D125A mutant but requires other viral proteins or products in the context of 
infection. 
 
To determine if the reduced viral protein synthesis was due to a reduction in viral 
mRNA, we performed quantitative real-time RT-PCR on RNA isolated from infected 
cells.  Cells were infected with rVSV-wt or rVSV-D125A at an MOI of 10 and RNA 
extracts were prepared at increasing times post infection.  The amount of genomic RNA 
was quantitated by RT-PCR using a VSV genomic standard (Fig. 4-7A), and when the 
ratio of P mRNA to genomic RNA was quantitated and we found the amount of P mRNA 
per genome was 3 fold higher at 5 hpi and 6 fold higher at 7 hpi in rVSV-D125A infected 
cells when compared to rVSV-wt infection (Fig 4-7B).  These data showed that a 
decrease in viral mRNA synthesis was not responsible for the reduced viral protein 
synthesis seen with the D125A mutant.  In fact, there was significantly more viral mRNA 
in the mutant infected cells than wild-type cells. 
 
To find out if wild-type M could rescue the protein synthesis defect of the D125A 
mutant, we used a synchronized fusion assay in a co-infection experiment with rVSV-wt 
and rVSV-D125A.  Cells were mock infected, infected with rVSV-wt (MOI 1), rVSV-
D125A (MOI 10), or rVSV-wt (MOI 1) and rVSV-D125A (MOI 10) in the presence of 
NH4Cl to synchronize the entry of virions (Chapter 2).  This technique was used for the 
co-infection experiments because we have observed an increase in cells expressing both 
green fluorescent protein and red fluorescent protein from separate viral genomes in co-
infected cells when fusion is synchronized as compared to normal (non-synchronized)  
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Figure 4-6.  Time course of viral protein synthesis by 35S-methionine metabolic 
labeling. 
(A) SDS-PAGE fluorography of 35S-methionine pulse-labeled BHK-21 cell lysates from 
mock infected (lane 1), rVSV-wt (lanes 3, 5, 7, and 9 ), or rVSV-D125A (lanes 2, 4, 6, 
and 8) infected cells at increasing time points post infection.  (B) Quantification of the 
difference in protein labeled (mutant N/ wt N protein) as analyzed by phosphorimaging 
software at 8 hours post infection shows an 80% loss in protein synthesis in rVSV-
D125A infected cells.  (C) 35S-methionine pulsed BHK-21 cell lysates from cells 
transiently expressing D125A (lane 1) or Mwt (lane 2).  (D) 35S-methionine labeled 
protein from rabbit reticulolysates of an in vitro transcription and translation of D125A 
(lane 1) and Mwt (lane 2).
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Figure 4-7.  Quantitative real-time RT-PCR of virus genomes and mRNA during 
rVSV infection. 
To rule out viral mRNA as the limiting factor in the reduction in protein synthesis at late 
time points during infection, RT-PCR was performed on BHK-21 cells infected with 
rVSV-wt (Wt) and rVSV-D125A (D125A).  (A) Genome equivalents (based on purified 
VSV genomic RNA standards) of RNA extracted from cells at increasing time points 
post infection, measured by RT-PCR using SYBR green.  (B) Levels of P mRNA were 
determined using quantitative RT-PCR and the –Wt and D125A mRNA to genome 
equivalents ratio was determined.  rVSV-D125A infection leads to more mRNA per 
genome at 7 hours post infection showing that reduction in viral message did not effect 
protein translation. 
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infection conditions (Watanabe, Mire, and Whitt, unpublished data).  At 9 hpi cells were 
pulse-labeled with 35S-methionine and analyzed by SDS-PAGE and phosphorimaging 
(Fig. 4-8).  We observed that co-infection could partially rescue protein synthesis at this 
time point post infection (Fig. 4-8A lane 3 compared to 1) and was up to 60% of rVSV-
wt infected cells (Fig. 4-8A lane 4 and Fig. 4-8B).  These data showed that the D125A M 
protein is not a dominant negative mutant for the protein synthesis defect and could be 
partially rescued by the wild-type protein. 
 
 
rVSV M loop mutants show defects in assembly.  While we observed reduced 
viral protein translation beginning at 6 hpi, we also found that rVSV-D125A titers were 
one-log below wild-type (Fig. 4-4A) at 4 hpi when protein synthesis was similar between 
the two viruses (Fig. 4-6A, lanes 4 and 5).  To determine if virus assembly was affected 
by the D125A mutation, we analyzed other assembly functions of M.  It was previously 
observed that M protein associates with RNPs at the plasma membrane of VSV infected 
cells (157).  To assess if this association was affected by the D125A mutation, we stained 
infected cells for M and N protein at 4 hpi and compared the distribution of the mutant 
and wild-type proteins by laser scanning confocal microscopy.  The images in figure 4-
9A are representative of infected cells stained with anti-M monoclonal antibody (23H12) 
conjugated to FITC and anti-N monoclonal antibody (10G4) conjugated to rhodamine 
and examined by 488nm and 543nm laser excitation.  We observed similar distributions 
for the wild-type (Wt) and mutant (D125A) M proteins, but when we compared the N 
distributions in the D125A and wild-type (Wt) infected cells we found the N distribution 
during wild-type infection to be more closely associated with the cell periphery near the 
plasma membrane (Fig. 4-9A).  These data suggested that RNPs were not being 
assembled at the plasma membrane as efficiently in rVSV-D125A infected cells when 
compared to rVSV-wt infection and we reasoned that this may affect the amount of virus 
released. 
 
To determine if release of virions from infected cells was lower in rVSV-D125A 
infected cells when compared to rVSV-wt infected cells, we performed viral budding 
assays at 4 hpi.  Cells were mock infected, infected with rVSV-wt, or rVSV-D125A at an 
MOI of 10 and at 3 hpi were pulse-labeled with 35S-methionine for 1 hour.  At 4 hpi, 
virus was purified from the cell supernatants, cell lysates were collected, and both 
released virus and viral proteins in cell extracts were analyzed by SDS-PAGE and 
phosphorimaging.  When the amount of labeled virus in the supernatant was compared to 
the cell lysates from rVSV-D125A it was found that only 1.3% (Fig. 4-9B lanes 5 and 6) 
of labeled N protein was released from cells and rVSV-wt had 12% (Fig. 4-9B lanes 3 
and 4) labeled N protein released.  We then determined whether this effect could be 
rescued by the wild-type M protein and we performed synchronized fusion co-infection 
experiments as mentioned above but in the context of the viral budding assay just 
explained.  We observed that infection in the presence of NH4Cl did not affect virus 
release for rVSV-wt and rVSV-D125A at 4 hpi since the results were similar to that seen 
in Figure 4-9 with wild-type releasing 16% (Fig. 4-9C lanes 1 and 2) of labeled N and the 
mutant releasing 0.9% (Fig. 4-9 lanes 3 and 4).  However, we determined that co-
infection of the virions resulted in partial rescue of virion release as labeled N protein  
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Figure 4-8.   35S-methionine metabolic labeling of cells co-infected with rVSV. 
(A) Viral protein synthesis in BHK-21 cells was examined in mock infected (lane 1), 
infected with rVSV-wt (MOI 1, lane 4), rVSV-D125A (MOI 10, lane 2), or co-infected 
(lane 3) by 35S-methionine pulse labeling at 9 hours post infection and cell lysates were 
analyzed by fluorography.  (B) Quantification of protein synthesis using 
phosphorimaging shows a 60% rescue in co-infected cells. 
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Figure 4-9.  Analysis of assembly defects for rVSV-D125A. 
(A) To characterize the distribution of the N and M proteins during assembly, laser 
scanning confocal microscopy of rVSV-wt (Wt) or rVSV-D125A infected cells (MOI 10) 
at 4 hours post infection was performed.  Infected cells were fixed and labeled for the M 
(M mAb 23H12 conjugated to FITC) and N (N mAb 10G4 conjugated to rhodamine) 
proteins.  Magnification using 100X objective for a 1 µm slice in the center of the cell.  
(B) Fluorography of cell lysates (odd numbered lanes) and released virus (even numbered 
lanes) from a viral budding assay of cells mock infected (lanes 1 and 2), infected with 
rVSV-wt (lanes 3 and 4), or rVSV-D125A (lanes 5 and 6) pulse-labeled with 35S-
methionine for an hour at 3 hours post infection (hpi).  Phosphorimaging was used for the 
quantification of labeled N protein in the supernatant (released virus) versus cell lysates.  
(C) Co-infection data from viral budding assays as performed and quantified in (B).  (D) 
RNP exchange assay.  rVSV-wt (Wt RNP) or rVSV-D125A (D125A RNP) RNPs at 10, 
50, or 100 µg were incubated with 35S-methionine labeled Mwt or D125A produced by in 
vitro translation and the mixtures were ultracentrifuged over sucrose cushion to separate 
RNPs with associated M proteins incorporated input M (P; pellet) and un-incorporated M 
(S; supernatant). 
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released was near 8% (Fig. 4-9C lanes 5 and 6).  These results suggested the D125A 
mutant M was not dominant negative for reduction virion assembly and release. 
 
To determine if the decrease in virus release was due to inefficient condensation 
of RNPs by the D125A loop mutation, we performed an RNP exchange assay.  Ten, 50, 
or 100 µg of purified rVSV-wt or rVSV-D125A was detergent solubilized in the presence 
of 35S-methionine labeled Mwt or D125A that had been synthesized in an in vitro 
translation system to allow exchange of the labeled M proteins with the RNPs of the 
virions.  The RNPs were then separated from the supernatant by ultracentrifugation and 
the pellet and supernatant analyzed by SDS-PAGE and radiofluorography.  We observed 
that the Wt RNPs did not incorporate any input 35S-methionine labeled M protein even 
with 100 µg of virus where more RNPs are available to exchange with input M (Fig. 4-
9D, Wt RNP, P), while the D125A RNPs exchanged with each of the input labeled M 
proteins (Fig. 4-9D, D125A RNP, P).  These data suggested that the D125A M protein 
was less tightly associated with the RNP derived from D125A virus and therefore 
resulted in exchange with input M. 
 
 
Reduction in viral protein synthesis is not due to classical host responses, 
apoptosis, or autophagy.  To determine if the classical host responses to RNA viruses 
that can cause inhibition of viral and host protein synthesis were responsible for the 
reduced protein synthesis seen in rVSV-D125A infected cells, we examined the end 
products of RNase L and PKR activation.  Cells were mock infected, infected with rVSV-
wt, or rVSV-D125A at an MOI of 10 and at increasing times post infection RNA was 
extracted for formaldehyde agarose electrophoresis (Fig. 4-9A) or cells lysates were 
separated by SDS-PAGE and analyzed by immunoblotting (Fig. 4-9B).  To determine if 
RNase L was activated resulting in more degraded ribosomal RNA (rRNA) in the rVSV-
D125A infected cells, we examined extracted RNA on a RNA denaturing gel and 
observed that there were no degradation products from the 28S and 18S rRNA (Fig. 4-
10A) where one would expect to see these products after RNase L activation.  We then 
examined the cell lysates by immunoblotting for phosphorylated eIF2α to determine if 
PKR activation was higher in cells infected with rVSV-D125A when compared to rVSV-
wt infection.  We observed no increase in phosphorylation of eIF2α in rVSV-wt and 
rVSV-D125A infected cells (Fig. 4-10B lanes 1-3, respectively).  Taken together these 
data showed that neither classical response was involved in the decreased protein 
synthesis observed in D125A infected cells. 
 
We used HeLa cells to analyze interferon, apoptosis, and autophagy responses to 
rVSV-D125A and rVSV-wt infections because the reagents required the use of human 
cells or only recognized human proteins.  To determine if the reduced titers and protein 
synthesis phenotype of the D125A mutant were found in human cells we infected HeLa 
cells at an MOI of 10 and assessed total protein synthesis and virus production as 
described for the BHK-21 cell experiments.  As seen in BHKs, protein synthesis was 
decreased for the rVSV-D125A (Fig. 4-11A lanes 6 and 8) when compared to rVSVwt 
(Fig. 4-11A lanes 5 and 7) but the reduction was somewhat delayed in HeLa and occurred 
at 6 hpi versus 4 hpi.  The rVSV-D125A viruses also grew to lower titers in HeLa cells 
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Figure 4-10.  Analysis of PKR and RNaseL activation in rVSV-D125A infected cells. 
BHK-21 cells were mock infected (lane 1), infected at MOI 10 with rVSV-wt (lane 2) or 
rVSV-D125A (lane 3) and at 7 hours post infection cell extracts were collected and RNA 
was analyzed by denaturing gel electrophoresis (A) or by immunoblot analysis (B).  (A) 
2% formaldehyde-agarose gel of 2μg total input RNA to assess RNaseL activation.  (B)  
Immunoblots using monoclonal antibodies to Tubulin, eIF2α, and phosphorylated eIF2α 
was used to assess PKR activation. 
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Figure 4-11.  Analysis of reduced protein synthesis and host cell response in HeLa 
cells. 
(A) HeLa cells were infected with rVSV-wt (lanes 1, 3, 5, and 7) or rVSV-D125A (lanes 
2, 4, 6, and 8) at an MOI of 10 and pulse-labeled with 35S-methionine at increasing times 
post infection.  (B) rVSV-wt (Wt) and rVSV-D125A (D125A) titers at 8 hours post 
infection from single-cycle infection in HeLa cells.  (C) HeLa cells transfected with a 
plasmid that expressed luciferase under the control of the IFNβ promoter were treated 
with 125U of human IFNβ, or infected with rVSV-wt (Wt) or rVSV-D125A (D125A) 
and cell lysates were assessed for luciferase activity at 6 hours post infection.  (D) 
Immunoblots of HeLa cell lysates from mock infected/untreated (lane 1) or rapamycin 
treated (lane 2) cells, and cell lysates from rVSV-wt (lanes 3, 5, and 7) or rVSV-D125A 
(lanes 4, 6, and 8) infected cells at increasing times post infection detecting 
phosphorylated eIF2α, full-length and cleaved caspase 3, phosphorylated eIF4G, LC3B, 
VSV M, and tubulin using monoclonal antibodies.
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(also in NIH 3T3 and Vero cells; data not shown) when compared to rVSV-wt (Fig. 4-
11B).  These data showed the effects on protein synthesis and assembly were not 
restricted to BHK cells but also occurred in HeLa cells. 
 
To determine if rVSV-D125A infection could lead to a more robust interferon 
response, we transfected cells with a luciferase reporter plasmid under the control of the 
interferon (IFN)β promoter and at 5 hours post transfection the cells were treated with 
human (hu)IFNβ, or they were infected with rVSV-D125A or rVSV-wt.  At 6 hpi we 
observed no difference between the luciferase activity from the IFNβ promoter in cells 
infected with either virus (Fig. 4-11C).  These data showed that in these cells increased 
IFN inducible gene expression is not responsible for the reduction in rVSV-D125A 
infected cells. 
 
To determine if eIF2α phosphorylation, apoptosis, or autophagy could cause 
reduced protein synthesis in rVSV-D125A infected HeLa cells when compared to rVSV-
wt infection, cells were mock infected or treated with rapamycin to induce autophagy as a 
control, and were infected (MOI 10).  Cell lysates were collected at 6, 10, and 12 hpi and 
analyzed by immunoblot.  Phosphorylation of eIF2α was enhanced in rVSV-D125A 
infected cells at 12 hpi but not at 6 hpi (Fig.4-11D lanes 8 and 6, respectively) where we 
observed reduced viral protein synthesis suggesting PKR activation is not involved in this 
effect seen at earlier times post infection.  Apoptosis was ruled out as a possible 
mechanism for this effect as there was no difference in the cleavage of caspase 3 between 
rVSV-D125A and rVSV-wt infected cells (Fig. 4-11D, lanes 3-8).  To examine the role 
of autophagy in reduced viral protein synthesis we examined proteins affected by this 
process and compared them between the two types of virus infected cells.  Rapamycin 
treatment resulted in the complete conversion of LC3 protein to the LC3B form and the 
dephosphorylation of eIF4G, which is an important protein in the initiation of protein 
synthesis (Fig. 4-11D lane 2).  However, we observed no difference between these 
autophagy markers within cells infected with rVSV-D125A or rVSV-wt.  Overall, these 
data showed that PKR activation, induction of apoptosis, and autophagy were not 
involved in the reduction in viral protein synthesis seen in rVSV-D125A infected cells. 
 
 
rVSV infection does not reduce cap-independent protein synthesis.  To 
determine if protein synthesis from a Type 2 internal ribosome entry site (IRES) could be 
affected in rVSV-D125A infected cells, we transfected BSR cells constitutively 
expressing T7 polymerase with a plasmid that has a T7 promoter used to produce an 
mRNA with an encephalomyocarditis virus (EMCV) IRES for cap-independent protein 
synthesis of a luciferase reporter gene.  At 18 hours p.t., cells were mock infected, treated 
with cycloheximide, or infected with rVSV-wt or rVSV-D125A at an MOI of 10.  Cell 
lysates were then analyzed for luciferase activity in a luminometer at increasing times 
post infection.  Luciferase activity of cell lysates from mock infected and cycloheximide 
treated BSRs at 6 hpi (of treatment) showed the basal level and background luciferase 
activity, respectively (Fig. 4-12).  It is interesting to note that at 6 hpi both rVSV-wt and 
rVSV-D125A infected cell lysates have higher luciferase activity than the mock infected 
cells.  This effect may be due to restriction of host mRNA export from the nucleus which  
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Figure 4-12.  EMCV/IRES expression of luciferase in rVSV infected BSR cells. 
BSR cells constitutively expressing T7 were transfected with a plasmid that expresses 
IRES-luciferase from a T7 promoter.  Eighteen hours post transfection; BSR cells were 
mock treated/infected or treated with cycloheximide, or infected rVSV-wt (Wt) or rVSV-
D125A (D125A).  Luciferase activity was measured at 6 hours post treatment for 
cycloheximide treated cells and at increasing times post infection for infected cells.
 90
would reduce the competition for ribosomes by the cytosolic luciferase mRNA since in 
another experiment we found that both viruses were capable of limiting luciferase 
expression from a chicken actin promoter, which occurs in the nucleus by RNA 
polymerase II (data not shown).  The results of this experiment also showed that the 
luciferase activity of cell lysates from both viruses did not significantly differ over the 
course of infection suggesting that the reduced protein synthesis seen at increasing time 
points post infection in rVSV-D125A infected cells only affected synthesis of proteins 
produced by a cap-dependent mechanism. 
 
 
Discussion 
 
The crystallization of the VSV M protein was made possible by proteolytic 
cleavage of an exposed loop that prevented the protein’s self-association (10, 65-68).  
The self-association is affected by high ionic concentrations (67) and these salt conditions 
have also been shown to cause the decondensation of skeletons in an M-dependent 
manner (154).  Altogether, these observations suggested that the exposed loop may be 
involved in the assembly of virions in regards to condensation of RNPs into skeletons.  
Others made mutations at amino acids 121 to 124 within this loop and a minor assembly 
defect was observed but there was an unexpected reduction in viral protein synthesis for 
this mutant rVSV (35).  Here we report on a mutational analysis of different amino acids 
found within this loop with a focus on the conserved aspartate at residue 125.   
 
There were no discernable differences in cellular distribution and budding activity 
for the M loop mutants when compared to Mwt.  However, rVSV encoding only four of 
the eight mutations could be recovered after multiple attempts (n = 6 per virus).  These 
data suggested that the amino acids and size of the loop were important for recovery and 
therefore for assembly of virus.  Indeed, we saw reduced growth kinetics (Fig. 4-4A) and 
virus budding (Fig. 4-9B) for the four rVSV M loop mutants that were recovered when 
compared to wild-type rVSV.  We also observed what appeared to be a build-up of N 
protein (RNPs) within rVSV-D125A infected cells when compared to rVSV-wt (Fig. 4-
9A) and we reasoned that this may be due to inefficient condensation of RNPs at the 
plasma membrane much like the build-up of uncondensed RNPs that occurs in the M 
protein temperature-sensitive mutant (tsG33) infected cells at non-permissive temperature 
(160).  There were also additional observations that suggested RNPs may be inefficiently 
condensed.  One was the high viral mRNA to genome ratio found in the rVSV-D125A 
infected cells when compared to rVSV-wt infection as M condensation of the RNP is 
thought to inhibit transcription (163).  The other was that rVSV-D125A RNPs could 
exchange with more Mwt or the M D125A loop mutant proteins when compared to 
rVSV-wt RNPs (Fig. 4-9D) where exchange of M protein is thought to be indicative of 
the condensed nature of RNPs (57).  These data correlated with the proteolytic cleavage 
data that suggested the exposed loop may be important in virion assembly (65, 66).  
These were not the only observations that we made in regards to the M loop mutations as 
we also noticed a reduction in viral protein synthesis (Fig. 4-5 and 4-6A). 
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The observation that the rVSV-D125A mutant had a reduction in protein 
synthesis was also observed previously with different M loop mutations (35).  The 
assembly defects and higher viral mRNA to genome ratio phenotypes of the rVSV-
D125A mutant led us to reason that there may be more viral products within infected 
cells to provide a more robust antiviral response to the D125A mutant when compared to 
wild-type.  To test the classical antiviral responses of cells to RNA virus infection that 
result in reduced protein synthesis, we compared PKR and RNaseL activation (196) in 
cells infected with rVSV-D125A and rVSV-wt for differences in phosphorylation of 
eIF2α and degradation of rRNA and found these were not responsible for the reduction 
(Fig. 4-10).  The expression IFN which leads to subsequent signaling events that produce 
and antiviral response that controls VSV replication (197), was also we examined by 
luciferase expression from an IFNβ promoter and it was found that there was no 
difference in the induction of IFN between the rVSV-wt and D125A mutant viruses, 
suggesting this was not responsible for the reduced viral protein synthesis (Fig. 4-11C).  
The experiment examining activity from the IFNβ promoter was performed in HeLa 
cells, but another cell line with a more robust IFN response like plasmacytoid dentritic 
cells (pDCs) may be a more appropriate cell to infect and to evaluate potential differences 
before completely disregarding the role of this pathway. 
 
VSV can cause apoptosis in infected cells (106) but enhanced apoptosis did not 
appear to be involved in this reduction as there was no difference in cleavage of pro-
Caspase 3 to caspase 3 when loop mutant and wild-type infected cells were compared 
(Fig. 4-11D).  Recently, it was reported that the IFN response to VSV infection in pDCs 
was toll-like receptor 7 (TLR7) and autophagy dependent (118).  This revealed a new 
model for how cells can autophagocytose viral ssRNA and traffic the RNA to TLR7.  We 
therefore measured this response by examining the conversion of LC3 to LC3B in 
infected cells and found no difference between the virus infected cells.  Altogether, these 
results suggest that the reduced viral protein synthesis may not be a host cell response, 
our analysis was not exhaustive as other responses like those through the cytosolic 
pattern recognition receptors such as RIG-I could be involved (187). 
 
Recently, the VSV field has gained insight on how control of the translation of 
host and viral proteins is accomplished in VSV infected cells.  It was shown that 
dephosphorylation of the eIF4E complex was responsible for the reduction of host protein 
synthesis (34) and phosphorylation of eIF2α controls viral protein synthesis at later times 
post infection (33).  A new model has been proposed for translation during infection 
where dephosphorylation of eIF4E results in inhibition of host protein synthesis and the 
host mRNA is then shuttled to inactive mRNPs which in turn allows for newly made viral 
mRNA to be translated (208) and this process may be enhanced between 4 to 8 hpi by M 
(13, 35, 208).  This is particularly interesting since we observed a reduction in viral 
protein synthesis from 4 to 8 hpi (Fig. 4-6A), which we assumed was the result of a host 
response since protein synthesis was similar at early times post infection.  However this 
may reflect the inability of the D125A loop mutant to positively regulate viral protein 
synthesis. 
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Eukaryotic protein translation initiation is a complex process that requires many 
co-factors but the cap-independent translation of mRNA from picornaviruses such as 
encephalomyocarditis virus (EMCV) requires a smaller number of initiation factors when 
compared to the number required for cap-dependent translation initiation (167).  EMCV 
mRNA contains a 5’ untranslated region (UTR) that has an internal ribosome entry site 
(IRES) (83, 89) and translation from the IRES in vitro only requires ATP, eIF2, eIF3, 
eIF4A or eIF4E, and the central portion of eIF4G (167).  Although it is still possible that 
the reduction in viral protein synthesis was due to a host response that was enhanced due 
to inefficient virus assembly, our results suggested that the effect was more likely due to 
the inability of the loop mutant proteins to up-regulate VSV translation.  To determine if 
any of the factors required for translation from the EMCV IRES were affected during 
rVSV-D125A infection, we examined translation of luciferase expressed from an EMCV 
IRES and found it was not significantly affected by rVSV-D125A infection.  
Interestingly, there was an increase in luciferase at 6 hpi in infected cells when compared 
to mock infected cells (Fig. 4-12) where newly made viral mRNA should be 
preferentially translated (208).  These data implicate that eIF4E may be the factor 
involved in the protein synthesis effect observed during rVSV M loop mutant infections 
(35) since it is the only major initiation factor that is not required for EMCV IRES 
protein translation initiation but is required for cap-dependent β-globin mRNA translation 
(167).  Importantly, it has been shown that VSV infection affects host protein synthesis 
by dephosphorylation of eIF4E (34) and a model was proposed that the short UTR of 
VSV mRNA did not require phosphorylated eIF4E for translation initiation (33) and 
therefore viral protein synthesis was not affected.  The short UTR model was tested by 
expression of protein from rVSV genomes that had long UTRs on the mRNA and it was 
observed that the mRNA with long UTRs were translated as efficiently as mRNA with 
shorter UTRs (209).  This led to the model suggesting that it was the timing of the mRNA 
synthesis that allowed for preferential translation (208).  The data presented here  
together with that published by others (13, 33-35, 208, 209) suggests that M protein may 
regulate viral translation by playing a supporting role for the loss of phosphorylated 
eIF4E and that the exposed loop of M (amino acids 121 to 125) is involved in this 
regulation to allow cap-dependent translation of newly synthesized mRNA.  However, 
not only may this loop be involved in protein translation enhancement, but also we show 
that it is required for efficient assembly.  Whether these two phenotypes can be separated 
genetically will require additional investigation. 
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Chapter 5:  General Discussion 
 
 
VSV Entry and Uncoating 
 
Entry and uncoating of enveloped viruses has been examined for the past three 
decades but new technologies over the past 10 years have made it possible to gain further 
insight into these processes [reviewed in (114, 136)].  Virions entering a cell have highly 
condensed genomes protected by proteins.  Before these particles can replicate in a host 
cell, after fusion and entry, uncoating must occur and this is described as the dissociation 
of the proteins condensing the genome.  Once the genome has uncoated, replication of the 
virus can begin and this process is the opposite of what occurs to package the virus for 
release.  Here lies the question; how can a virus accomplish these two distinct events 
using the same protein?  It has been shown how influenza virus, another enveloped 
negative-strand RNA virus, can accomplish this through virus-host interactions.  Studies 
on Sindbis virus and Semliki Forest virus have also suggested virus-host interactions in 
uncoating.  Based on the available details for VSV entry and influenza, Sindbis, and 
Semliki Forest virus entry and uncoating, I am proposing a model for VSV entry and 
uncoating with a focus on the events that occur right before fusion and after release into 
the cytosol. 
 
 
Upon entry, the VSV virion must be disassembled.  The structure of the virion 
is composed of a helical nucleocapsid, containing L-P-N-RNA-M, surrounded by a 
membrane derived from an infected host cell membrane with transmembrane, trimeric G 
proteins protruding from the surface.  The RNA genome is encapsidated by N protein and 
RNA-dependent RNA polymerase, consisting of the L and P proteins, is associated with 
this ribonucleoprotein complex (199).  The L-P-N-RNA complex makes up the 
ribonucleoprotein particle (RNP) which is coiled into a tightly packed helix and the M 
protein condenses the RNP into this tightly packed helix, called the skeleton (153, 154). 
Also a population of membrane bound M anchors the skeletons to the viral membrane 
(31, 151).  Viral uncoating, in the case of VSV, is regarded as the dissociation of M from 
RNPs and is an essential step in entry (130).  Without the release of M protein 
transcription of viral mRNAs (productive infection) cannot proceed since it has been 
shown that M protein inhibits transcription (32, 44, 212). 
 
 
VSV entry.  When VSV enters the host cell through the clathrin-mediated 
endocytic pathway (139), it uses the decreasing pH of endocytic organelles as a trigger 
for fusion in order to penetrate the cell as is the case for influenza virus (207).  In our 
model, VSV virus attaches to the surface of a cell and is endocytosed by coated vesicles 
(Fig. 5-1A) and transported through the endosomal pathway to early endosomes (Fig. 5-
1B).  In early endosomes (189), pH-dependent fusion of the endosomal and viral 
membrane occurs (Fig. 5-1C) and the G protein is directly responsible for these entry 
steps (18, 82, 134, 161, 198, 211).  Our model presents early endosomes as the location  
 94
 95
Figure 5-1.  VSV entry model. 
(A) Attachment to the cell surface by VSV.  (B) Subsequent clathrin-mediated 
endocytosis of a VSV particle in a coated pit (orange stars depict clathrin scaffolding) 
that leads to Rab5 dependent trafficking to the early endosomes where a pH-dependent 
conformational change occurs for G (C) resulting in acidification of the virion interior 
(D).  Acidification of interior of the virion has an effect on the M protein (E, blue-
bordered stars) and results in an enhanced dissociation of M after fusion (F).  The bulk of 
M remains associated with endosomes and is trafficked to the recycling endosomes where 
M is thought to be located at the point of fusion (G).  A smaller fraction of M is released 
into the cytosol and reaches the NPCs in a microtubule and actin independent manner 
(H).  Events observed in steps G and H correlate with replication of RNPs that have 
uncoated.  
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of fusion and release of RNPs based on Rab5 dominant negative (189) and nocodazole 
(42) studies that indicate fusion does not require transport to late endosomes as another 
group has recently suggested (117). 
 
 
Acidification of the VSV interior and its effect on M.  Our model proposes that 
the interior of VSV becomes acidified over the course of entry in a G-dependent manner 
(Fig. 5-1D).  This is a different mechanism than the one used for influenza as discussed in 
Chapter 3 (Discussion section) but results in a similar enhancement of the uncoating of 
the M protein.  Since the M associated with purified RNPs is not sensitive to acidic 
conditions [(130), and our lab’s unpublished data] our model has the pH affecting the 
interaction between the membrane bound and RNP bound M (Fig. 5-1E, blue-bordered 
stars) which allows the release of RNPs from endosomes after fusion.  The release of 
RNPs could be a general unwinding of the RNP from one end or release of the condensed 
RNP as depicted in figure (5-1F). 
 
 
Completion of uncoating and the subsequent distribution of M.  In our model, 
after the release of the skeleton from the membrane bound M, the bulk of the M protein 
remains associated with endosomes that traffic to the recycling endosomes (Fig. 5-1G).  
Although binding to one side of the endosome by the G of unfused virions or the re-
association of released M protein to endosomes cannot be completely ruled out, the 
separation of M and the RNPs at these locations and the fact that only misfolded 
temperature-sensitive M mutants have been seen to associate with vesicles in cells (132) 
suggests that these are points of fusion.  The RNP associated M then releases from the 
RNPs into the cytosol as previously proposed (130) and reaches the nucleus and binds the 
NPCs by diffusion (Fig. 5-1H).  Diffusion of M to the NPCs is proposed here since the 
protein could reach the nucleus and separate from RNPs without the need for actin or 
microtubules; however an undiscovered mode of trafficking perhaps using RaeI or 
vesicular transport that is not dependent on these two cytoskeletal elements cannot be 
ruled out.  Brefeldin A inhibition of retrograde transport could rule out that transport 
process in the trafficking to NPCs (27).  siRNA knock down or use of dominant negatives 
of the known Rab GTPases involved in vesicular trafficking may also be ways to rule out 
known vesicular pathways that are commandeered by bacterial pathogens to survive 
within host cells (23).  The binding of M to NPCs has been proposed previously as the 
first cytopathic effect of VSV (60) and one could reason that directly after release of M 
the association with the NPCs would give the virus the ability to prevent antiviral 
responses requiring gene expression before the virus has started replication. 
 
 
VSV Assembly 
 
The assembly of VSV virions, which is the reverse process of uncoating, has been 
studied extensively and a model has been proposed by our lab (90).  Proteolytic cleavage 
of an exposed loop prevented M self-association (10, 65-68) and this self-association has 
been implicated in condensation of skeletons (154).  These observations suggested that 
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the exposed loop may be involved in the assembly of virions in regards to condensation 
of RNPs into skeletons.  Others made mutations at amino acids 121 to 124 within this 
loop and a minor assembly defect was observed, but there was an unexpected reduction 
in viral protein synthesis for this mutant rVSV (35). 
 
The current model from Jayakar, et al. (90), outlines 5 steps in VSV assembly.  
The first step is encapsidation of anti- or genomic RNA by the N protein in the cytoplasm 
while some M may bind to the nucleocapsid but not enough for condensation.  The 
second step occurs during N encapsidation of genomic RNA, where G protein is 
trafficked to microdomains at the cell surface forming favorable sites for condensation of 
RNPs by M protein.  The third step consists of M association at the plasma membrane 
(during steps 1 and 2) and condensation of RNPs into skeletons with cytosolic M protein 
at G-enriched microdomains.  At the fourth step, the condensation of skeletons resulting 
in eversion of the the plasma membrane resulting in an enveloped skeleton by recruitment 
of membrane and cytosolic M proteins, resulting in bullet shaped evaginations of the 
membrane.  In the final step of the model, the host cell multivesicular body (MVB) 
fission machinery associates with the PY motif of M through a ubiquitin ligase and this 
interaction, whether direct or indirect, results in fission and release of mature progeny 
virions. 
 
Based on the assembly model from our lab, I propose a model for the involvement 
of the exposed loop in efficient binding to and condensation of RNPs by M during VSV 
assembly.  Initiator M (Mi) has been proposed and is yet to be identified however 
nucleation sites are needed for full scale M self-association to occur (67) and one can 
imagine a scenario where Mi can bind to RNPs before they reach the plasma membrane 
to prime the RNPs for condensation by M protein undergoing self-association.  Also M 
inhibits viral transcription within infected cells and this does not necessarily occur at the 
plasma membrane so Mi could be responsible for the phenomenon.  The cleavage of the 
exposed loop of M by thermolysin resulted in Mth which could not form, nor be recruited 
into nucleation sites (65).  I propose a model where the conserved aspartate at residue 125 
is involved in the process of initial binding of Mi to RNPs (Fig. 5-2, between I. and II.) 
and the efficient condensation of RNPs at the plasma membrane (Fig. 5-2, V.) as 
evidenced by the build up of N protein, hyper-transcription of viral mRNA in rVSV-
D125A infected cells and the increased ability of the RNPs from virions to exchange with 
introduced M.  This model also includes the most recent model for how budding sites are 
formed, where RNPs and G initially associate at microdomains before incorporation of M 
at these sites (195) (Fig. 5-2, III.).  The importance of the hypervariable hinge region of P 
in assembly (43) may be the important factor in the initiation of association of RNPs at 
budding sites or for condensation by M (Fig. 5-2, III. and IV., respectively).  Also 
observations from Chapter 2 revealed M chimeras with large C-terminal fusions affect 
budding activity suggesting that the PY motif interactions with Nedd4 or an MVB 
complex are sterically hindered by these C-terminal extensions thereby reducing the 
budding activity of M protein (Fig. 5-2, VI.). 
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Figure 5-2.  VSV assembly model. 
(I.)  Genomic RNA is encapsidated by N protein while G protein trimers form 
microdomains at the virus budding site (II.).  Initiator (Mi, orange circles) has been 
proposed previously (90) and as described in the General Discussion the LXD sequence 
of the M protein may be important for forming nucleation sites formed by the Mi.  After 
the proposed binding of Mi to the RNP this complex is then trafficked to the plasma 
membrane where it associates in microdomains with G (III.) and then M (membrane 
bound green circles) is incorporated to these microdomains (IV.) as recently shown (195).  
The role for P, in particular residues 191 to 200, in assembly has been reported recently 
and it may be involved in steps III. or IV.  (V.) After the budding site has been formed 
the membrane bound M, Mi, and cytosolic M (black-rimmed green circles) participate in 
the helical condensation of the RNP and this process is proposed to be less efficient in M 
proteins with mutations in the LXD sequence.  (VI.) Progeny virions then bud from the 
host cell in an M protein PY motif dependent manner where it has also been shown that 
large C-terminal extensions affect budding. 
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VSV Translation 
 
Recently, a new model has been proposed for translation of viral proteins during 
infection where dephosphorylation of eIF4E results in inhibition of host protein synthesis 
and the host mRNA is then shuttled to inactive mRNPs which in turn allows for newly 
made viral mRNA to be translated (208).  The translation of newly made viral mRNA 
which occurs between 4 to 8 hpi, may be enhanced by M (13, 35, 208).  In Chapter 4 we 
observed a reduction in viral protein synthesis between 4 and 8 hpi and I propose here 
that the M D125A loop mutation results in the inability of the mutant to support viral 
protein synthesis. 
 
Based on the new virus translation regulation model mentioned above, our model 
proposes that M protein supports viral translation by playing a supporting role, after the 
dephosphorylation eIF4E, for cap-dependent translation of newly synthesized viral 
transcripts.  Based on the D125A phenotype, the exposed loop of M (amino acids 121 to 
125) is involved in this regulation (Fig. 5-3).  It has to be said that the protein translation 
and assembly effects have not been separated and for now we designate this loop as 
important for both of these events.  The alignment of proteins retreived from a PubMed 
blast search of the exposed loop of M revealed a potential LXD motif that could be 
important in one or both of the phenotypes observed for the loop mutants. 
 
 
Future Directions 
 
The models presented here are a combination of the current views from the 
literature and my work.  However, these models require further investigation to clarify 
the “black boxes” that still exist.  In the entry model (Fig. 5-1) for instance, the exact 
location of M that associates with the recycling endosomes after VSV entry can be 
visualized using photoconversion of diaminobenzidine (DAB) by Lumio-RedTM from 
rVSV-M-Lumio-Red virus for high resolution TEM.  In the assembly model (Fig. 5-2), 
the condensed nature of the LXD mutant RNPs can be further examined by light 
scattering analysis when compared to wild-type.  The spacing between the helical turns of 
the RNPs in TEM visualization could also be measured and analyzed for statistical 
significance to determine if there is any difference between the LXD mutant and wild-
type RNPs.  In the translation model (Fig. 5-3), the exact mechanism for how M supports 
viral protein synthesis from viral mRNA still needs to be examined.  In the model 
dephosphorylated eIF4E is present in the initiation complex and M is depicted in support 
but it may be that M replaces eIF4E in this complex altogether.  Further investigation into 
the idea that M may replace eIF4E is intriguing since the proteins are similar in size, have 
a pleiomorphic N-terminus, and similar crystal structure (20, 66).  This is particularly 
interesting since there is an unanswered question about why M is phosphorylated (98, 99) 
where phosphorylation may be required for the support of viral protein synthesis after 4 
hpi.  Analysis of viral protein synthesis after 4 hpi using phosphorylation site mutants 
could certainly a way to examine this hypothesis.  While there are “black boxes” that still 
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Figure 5-3.  VSV translational support model for M. 
(Left-hand column) After 4 hours post infection (hpi) cellular protein synthesis is 
inhibited by dephosphorylation of eIF4E and the sequestration of host mRNA to mRNPs 
(33, 208).  However, this model proposes that M can support viral protein synthesis after 
the dephosphorylation of eIF4E and the loop (yellow loop on red M) is important for this 
especially the LXD sequence of M, however the manner in which this occurs is open for 
speculation.
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exist in the models for VSV replication, additions to these models that help clarify the 
“black boxes” are important to the contribution of VSV as the prototype Rhabdovirus and 
may contribute to insights into replication of viruses within the order Mononegavirales.
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